COVID-19 Vaccine, Testing and Testing-Related Services Codes

COVID-19 and COVID-19-related Diagnosis Codes

Updated September 13, 2022

(COVID-19 vaccine, testing, and test-related procedure codes are billable for Uninsured Individuals with one or more of the diagnosis codes contained in this chart.)

ICD-10 Diagnosis Code	Code Description	Code Effective Date
B34.2	Coronavirus infection, unspecified	10/01/15
B97.21	SARS-associated coronavirus as the cause of diseases classified elsewhere	10/01/15
J12.81	Pneumonia due to SARS-associated coronavirus	10/01/15
J12.89	Other viral pneumonia	10/01/15
J20.8	Acute bronchitis due to other specified organisms	10/01/15
J22	Unspecified acute lower respiratory infection	10/01/15
J40	Bronchitis, not specified as acute or chronic	10/01/15
J80	Acute respiratory distress syndrome	10/01/15
J98.8	Other specified respiratory disorders	10/01/15
R05	Cough	10/01/15
R05.1	Acute cough	10/01/21
R05.9	Cough, unspecified	10/01/21
R06.02	Shortness of breath	10/01/15
R50.9	Fever, unspecified	10/01/15
U07.1	An emergency ICD-10 code of 'U07.1 COVID-19, virus identified' is assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing.	04/01/21
U09.9	Post COVID-19 condition, unspecified	04/01/22
Z03.818	Concern about possible exposure, ruled out by evaluation- Z03.818 Encounter for observation for suspected exposure to other biological agents ruled out.	10/01/15
Z11.52	Encounter for screening for COVID-19	01/01/21

Z11.59	Encounter for screening for other viral diseases	10/01/15
Z20.822	Contact with and (suspected) exposure to COVID-19	01/01/21
Z20.828	Exposure confirmed- Z20.828 Contact with and (suspected) exposure to other viral communicable diseases	10/01/15
Z23	Encounter for Immunization	10/01/15

CPT & HCPC Codes	Revenue Codes	Code Description	MaineCare Effective Date	Uninsured Coverage Effective Date	MaineCare End Date
91300	0636	Pfizer-BioNTech- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	12/11/20	03/11/21	
91301	0636	Moderna- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	12/18/20	03/11/21	
91303	0636	Johnson and Johnson- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use	02/27/21	03/11/21	04/12/21
91303	0636	Johnson and Johnson- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use	02/27/21	04/23/21	

91304	0636	Novavax- Severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based	07/13/22	07/13/22	
91305	0636	Pfizer- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation, for intramuscular use	01/03/22	01/03/22	
91306	0636	Moderna- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	10/20/21	10/20/21	08/31/22
91307	0636	Pfizer-BioNTech- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	10/29/21	10/29/21	
91308	0636	Pfizer-BioNTech- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	06/17/22	06/17/22	
91309	0636	Moderna-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	03/29/22	03/29/22	
91311	0636	Moderna- Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	06/17/22	06/17/22	

91312	0636	Pfizer-BioNTech- Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08/31/22	08/31/22	
91313	0636	Moderna- Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	08/31/22	08/31/22	
0001A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	12/11/20	03/11/21	
0002A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	12/11/20	03/11/21	
0003A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: third dose	08/12/21	08/12/21	
0004A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: booster dose	9/22/21	9/22/21	08/31/22

0011A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	12/18/20	03/11/21	
0012A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose	12/18/20	03/11/21	
0013A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	08/12/21	08/12/21	
0031A	0771	Johnson and Johnson- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose	02/27/21	03/11/21	04/12/21
0031A	0771	Johnson and Johnson- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose	04/23/21	04/23/21	
0034A	0771	Johnson and Johnson- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; booster dose	10/20/21	10/20/21	

0041A	0771	Novavax- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant,	07/13/22	07/13/22	
0042A	0771	preservative free, 5 mcg/0.5 mL dosage; first dose Novavax- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; second dose	07/13/22	07/13/22	
0051A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	01/03/22	01/03/22	
0052A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose	01/03/22	01/03/22	
0053A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose	01/03/22	01/03/22	
0054A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose	01/03/22	01/03/22	08/31/22

0064A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose	10/20/21	10/20/21	08/31/22
0071A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: first dose	10/29/21	10/29/21	
0072A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: second dose	10/29/21	10/29/21	
0073A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	01/03/22	01/03/22	
0074A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, trissucrose formulation; booster dose	05/17/22	05/17/22	
0081A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL	06/17/22	06/17/22	

		dosage, diluent reconstituted, tris-sucrose formulation; first dose			
0082A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	06/17/22	06/17/22	
0083A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	06/17/22	06/17/22	
0091A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years	06/17/22	06/17/22	
0092A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years	06/17/22	06/17/22	
0093A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years	06/17/22	06/17/22	

0094A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	03/29/22	03/29/22	08/31/22
0111A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose	06/17/22	06/17/22	
0112A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose	06/17/22	06/17/22	
0113A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose	06/17/22	06/17/22	
0124A	0771	Pfizer-BioNTech- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose	08/31/22	08/31/22	
0134A	0771	Moderna- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose	08/31/22	08/31/22	

M0201	0771	Additional payment for administering the COVID-	08/24/21	08/24/21	
		19 vaccine to certain Medicare patients in their			
		homes.			

Testing and Testing Related Services Codes (COVID-19 testing codes are bold.)

CPT &	- Lesting codes a			Uninsured Coverage	
HCPC	Revenue		Code Effective	Effective	Code End
Codes	Codes	Code Description	Date	Date	Date
71045	0320, 0324	Radiologic examination, chest; single view	01/01/18	03/18/20	
71046	0320, 0324	Radiologic examination, chest; 2 views	01/01/18	03/18/20	
	0350, 0352,				
71250	0359	Computed tomography, thorax; without contrast material	01/01/79	03/18/20	
80047	0300, 0301, 0309	Basic metabolic panel (Calcium, ionized) This panel must include the following: Calcium, ionized (82330) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea Nitrogen (BUN) (84520)	01/01/08	03/18/20	
80076	0300, 0301, 0309	Hepatic function panel This panel must include the following: Albumin (82040) Bilirubin, total (82247) Bilirubin, direct (82248) Phosphatase, alkaline (84075) Protein, total (84155) Transferase, alanine amino (ALT) (SGPT) (84460) Transferase, aspartate amino (AST) (SGOT) (84450)	01/01/00	03/18/20	
	0300, 0301,				
82550	0309	Creatine kinase (CK), (CPK); total	01/01/79	03/18/20	
83615	0300, 0301, 0309	Lactate dehydrogenase (LD), (LDH);	01/01/79	03/18/20	
84145	0300, 0301, 0309	Procalcitonin (PCT)	01/01/10	03/18/20	
84478	0300, 0301, 0309	Triglycerides	01/01/79	03/18/20	
84484	0300, 0301, 0309	Troponin, quantitative	01/01/97	03/18/20	
85025	0300, 0305, 0309	Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	01/01/87	03/18/20	
85347	0300, 0305, 0309	Coagulation time; activated	01/01/79	03/18/20	

	0300, 0305,				
85379	0309	Fibrin degradation products, D-dimer; quantitative	01/01/93	03/18/20	
	0300, 0305,				
85384	0309	Fibrinogen; activity	01/01/93	03/18/20	
	0300, 0305,				
85390	0309	Fibrinolysins or coagulopathy screen, interpretation and report	01/01/79	03/18/20	
	0300, 0305,				
85576	0309	Platelet, aggregation (in vitro), each agent	01/01/79	03/18/20	
	0300, 0305,				
85610	0309	Prothrombin time;	01/01/79	03/18/20	
	0300, 0302,				
86141	0309	C-reactive protein; high sensitivity (hsCRP)	01/01/02	03/18/20	
0.6210	0300, 0302,	Immunoassay for infectious agent antibody(ies), qualitative or	01/01/00	02/10/20	
86318	0309	semiquantitative, single step method (eg, reagent strip);	01/01/89	03/18/20	
		Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute			
	0300, 0302,	respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
86328	0300, 0302,	[COVID-19])	04/10/20	04/10/20	
00320	0307	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2	0 1/ 10/ 20	0 1/ 10/ 20	
86408	0302, 0310	(SARS-CoV-2) (Coronavirus disease [COVID-19]); screen	08/10/20	08/10/20	
	,	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2			
86409	0302, 0310	(SARS-CoV-2) (Coronavirus disease [COVID-19]); titer	08/10/20	08/10/20	
		Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2)			
86413	0302, 0310	(Coronavirus disease [COVID-19]) antibody, quantitative	09/08/20	09/08/20	
	0300, 0302,				
86602	0309	Antibody; actinomyces	01/01/93	03/18/20	
	0300, 0302,				
86710	0309	Antibody; influenza virus	01/01/93	03/18/20	
0.65.00	0300, 0302,	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	0.4/1.0/20	0.4/1.0/20	
86769	0309	(Coronavirus disease [COVID-19])	04/10/20	04/10/20	
		Infectious agent antigen detection by immunoassay technique, (eg, enzyme			
		immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay			
	0300, 0306,	[IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome			
87426	0300, 0300,	coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])	06/25/20	06/25/20	
07720	0307	Colona (11 to (cg, 57 Htb Co 1, 57 Htb Co 1 2 [CO 1 ID 17])	00,23,20	00/23/20	

		[Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza			
87428	0310	virus types A and B].	10/06/20	10/06/20	
87502	0300, 0306, 0309	Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types	01/01/11	03/18/20	
87635	0310	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	03/13/20	03/18/20	
87636	0310	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	10/06/20	10/06/20	
87637	0310	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	10/06/20	10/06/20	
87811	0310	Updated Descriptor 10/06/2020: Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	10/06/20	10/06/20	
93000	0730	Electrocardiogram, routine ECG with at least 12 leads; with interpretation	01/01/79	03/18/20	
93005	0730	and report Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	01/01/79	03/18/20	
93224	0731	External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	01/01/90	03/18/20	
93225	0730, 0731	External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; recording (includes connection, recording, and disconnection)	01/01/90	03/18/20	
93226	0730, 0731	External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; scanning analysis with report	01/01/90	03/18/20	

		External electrocardiographic recording up to 48 hours by continuous			
	0521, 0731,	rhythm recording and storage; review and interpretation by a physician or			
93227	0985,	other qualified health care professional	01/01/90	03/18/20	
		External mobile cardiovascular telemetry with electrocardiographic			
		recording, concurrent computerized real time data analysis and greater than			
		24 hours of accessible ECG data storage (retrievable with query) with ECG			
		triggered and patient selected events transmitted to a remote attended			
		surveillance center for up to 30 days; review and interpretation with report			
93228	0985	by a physician or other qualified health care professional	01/01/09	03/18/20	
		External mobile cardiovascular telemetry with electrocardiographic			
		recording, concurrent computerized real time data analysis and greater than			
		24 hours of accessible ECG data storage (retrievable with query) with ECG			
		triggered and patient selected events transmitted to a remote attended			
		surveillance center for up to 30 days; technical support for connection and			
		patient instructions for use, attended surveillance, analysis and transmission			
		of daily and emergent data reports as prescribed by a physician or other			
93229	0732	qualified health care professional	01/01/09	03/18/20	
		Telephone assessment and management service provided by a qualified			
		nonphysician health care professional to an established patient, parent, or			
		guardian not originating from a related assessment and management service			
	0450, 0459,	provided within the previous 7 days nor leading to an assessment and			
	0520, 0529,	management service or procedure within the next 24 hours or soonest			
98966	0960	available appointment; 5-10 minutes of medical discussion	01/01/08	03/18/20	
		Telephone assessment and management service provided by a qualified			
		nonphysician health care professional to an established patient, parent, or			
		guardian not originating from a related assessment and management service			
	0450, 0459,	provided within the previous 7 days nor leading to an assessment and			
	0520, 0529,	management service or procedure within the next 24 hours or soonest			
98967	0960	available appointment; 11-20 minutes of medical discussion	01/01/08	03/18/20	
		Telephone assessment and management service provided by a qualified			
		nonphysician health care professional to an established patient, parent, or			
		guardian not originating from a related assessment and management service			
	0450, 0459,	provided within the previous 7 days nor leading to an assessment and			
	0520, 0529,	management service or procedure within the next 24 hours or soonest			
98968	0960	available appointment; 21-30 minutes of medical discussion	01/01/08	03/18/20	
		Qualified nonphysician health care professional online digital assessment			
	0450, 0459,	and management, for an established patient, for up to 7 days, cumulative			
98970	0520, 0529	time during the 7 days; 5-10 minutes	01/01/21	01/01/21	

		Qualified nonphysician health care professional online digital assessment			
	0450, 0459,	and management, for an established patient, for up to 7 days, cumulative			
98971	0520, 0529	time during the 7 days; 11-20 minutes	01/01/21	01/01/21	
		Qualified nonphysician health care professional online digital assessment			
	0450, 0459,	and management, for an established patient, for up to 7 days, cumulative			
98972	0520, 0529	time during the 7 days; 21 or more minutes	01/01/21	01/01/21	
		Handling and/or conveyance of specimen for transfer from the office to a			
99000	0300	laboratory	01/01/79	03/18/20	
	0456, 0510,	Office or other outpatient visit for the evaluation and management of a new			
	0511, 0512,	patient, which requires these 3 key components: a problem focused history;			
	0513, 0514,	a problem focused examination; straightforward medical decision making.			
	0515, 0516,	Counseling and/or coordination of care with other physicians, other			
	0517, 0519,	qualified health care professionals, or agencies are provided consistent with			
	0520, 0521,	the nature of the problem(s) and the patient's and/or family's needs. Usually,			
	0526, 0528,	the presenting problem(s) are self-limited or minor, typically, 10 minutes			
99201	0529, 0982	are spent face-to-face with the patient and/or family.	04/01/16	03/18/20	12/31/20
	0456, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,				
	0517, 0519,	Office or other outpatient visit for the evaluation and management of a new			
	0520, 0521,	patient, which requires a medically appropriate history and/or examination			
	0526, 0528,	and straightforward medical decision making. When using time for code			
99202	0529, 0982	selection, 15-29 minutes of total time is spent on the date of the encounter.	01/01/92	03/18/20	
	0456, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,				
	0517, 0519,	Office or other outpatient visit for the evaluation and management of a new			
	0520, 0521,	patient, which requires a medically appropriate history and/or examination			
	0526, 0528,	and low level of medical decision making. When using time for code			
99203	0529, 0982	selection, 30-44 minutes of total time is spent on the date of the encounter.	01/01/92	03/18/20	

	0456, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,				
	0517, 0519,	Office or other outpatient visit for the evaluation and management of a new			
	0520, 0521,	patient, which requires a medically appropriate history and/or examination			
	0526, 0528,	and moderate level of medical decision making. When using time for code			
99204	0529, 0982	selection, 45-59 minutes of total time is spent on the date of the encounter.	01/01/92	03/18/20	
	0456, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,				
	0517, 0519,	Office or other outpatient visit for the evaluation and management of a new			
	0520, 0521,	patient, which requires a medically appropriate history and/or examination			
	0526, 0528,	and high level of medical decision making. When using time for code			
99205	0529, 0982	selection, 60-74 minutes of total time is spent on the date of the encounter.	01/01/92	03/18/20	
	0456, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,				
	0517, 0519,	Office or other outpatient visit for the evaluation and management of an			
	0520, 0521,	established patient, that may not require the presence of a physician or other			
	0526, 0528,	qualified health care professional. Usually, the presenting problem(s) are			
99211	0529, 0982	minimal.	01/01/92	03/18/20	
	0456, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,	Office or other outpatient visit for the evaluation and management of an			
	0517, 0519,	established patient, which requires a medically appropriate history and/or			
	0520, 0521,	examination and straightforward medical decision making. When using			
	0526, 0528,	time for code selection, 10-19 minutes of total time is spent on the date of			
99212	0529, 0982	the encounter.	01/01/92	03/18/20	

	0.45 0.540			1	
	0456, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,	Office or other outpatient visit for the evaluation and management of an			
	0517, 0519,	established patient, which requires a medically appropriate history and/or			
	0520, 0521,	examination and low level of medical decision making. When using time			
	0526, 0528,	for code selection, 20-29 minutes of total time is spent on the date of the			
99213	0529, 0982	encounter.	01/01/92	03/18/20	
	0456, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,	Office or other outpatient visit for the evaluation and management of an			
	0517, 0519,	established patient, which requires a medically appropriate history and/or			
	0520, 0521,	examination and moderate level of medical decision making. When using			
	0526, 0528,	time for code selection, 30-39 minutes of total time is spent on the date of			
99214	0529, 0982	the encounter.	01/01/92	03/18/20	
	0456, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,	Office or other outpatient visit for the evaluation and management of an			
	0517, 0519,	established patient, which requires a medically appropriate history and/or			
	0520, 0521,	examination and high level of medical decision making. When using time			
	0526, 0528,	for code selection, 40-54 minutes of total time is spent on the date of the			
99215	0529, 0982	encounter.	01/01/92	03/18/20	
		Observation care discharge day management (This code is to be utilized to			
		report all services provided to a patient on discharge from outpatient			
		hospital "observation status" if the discharge is on other than the initial date			
		of "observation status." To report services to a patient designated as			
		"observation status" or "inpatient status" and discharged on the same date,			
99217	0762, 0982	use the codes for Observation or Inpatient Care Services	01/01/94	03/18/20	

99218	0762, 0982	Initial observation care, per day, for the evaluation and management of a patient which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission to outpatient hospital "observation status" are of low severity. Typically, 30 minutes are spent at the bedside and on the patient's hospital floor or unit.	01/01/93	03/18/20	
99219	0762, 0982	Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission to outpatient hospital "observation status" are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.	01/01/93	03/18/20	
99220	0762, 0982	Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission to outpatient hospital "observation status" are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.	01/01/93	03/18/20	
99221	0657, 0987	Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of low severity. Typically, 30 minutes are spent at the bedside and on the patient's hospital floor or unit.	01/01/92	03/18/20	

		Initial hospital gara nor day, for the avaluation and management of a			
		Initial hospital care, per day, for the evaluation and management of a			
		patient, which requires these 3 key components: A comprehensive history;			
		A comprehensive examination; and Medical decision making of moderate			
		complexity. Counseling and/or coordination of care with other physicians,			
		other qualified health care professionals, or agencies are provided consistent			
		with the nature of the problem(s) and the patient's and/or family's needs.			
		Usually, the problem(s) requiring admission are of moderate severity.			
		Typically, 50 minutes are spent at the bedside and on the patient's hospital			
99222	0657, 0987	floor or unit.	01/01/92	03/18/20	
		Initial hospital care, per day, for the evaluation and management of a			
		patient, which requires these 3 key components: A comprehensive history;			
		A comprehensive examination; and Medical decision making of high			
		complexity. Counseling and/or coordination of care with other physicians,			
		other qualified health care professionals, or agencies are provided consistent			
		with the nature of the problem(s) and the patient's and/or family's needs.			
		Usually, the problem(s) requiring admission are of high severity. Typically,			
		70 minutes are spent at the bedside and on the patient's hospital floor or			
00222	0657 0097		01/01/02	02/19/20	
99223	0657, 0987	unit.	01/01/92	03/18/20	
		Subsequent observation care, per day, for the evaluation and management			
		of a patient, which requires at least 2 of these 3 key components: Problem			
		focused interval history; Problem focused examination; Medical decision			
		making that is straightforward or of low complexity. Counseling and/or			
		coordination of care with other physicians, other qualified health care			
		professionals, or agencies are provided consistent with the nature of the			
		problem(s) and the patient's and/or family's needs. Usually, the patient is			
		stable, recovering, or improving. Typically, 15 minutes are spent at the			
99224	0982, 0987	bedside and on the patient's hospital floor or unit.	01/01/11	03/18/20	
		Subsequent observation care, per day, for the evaluation and management			
		of a patient, which requires at least 2 of these 3 key components: An			
		expanded problem focused interval history; An expanded problem focused			
		examination; Medical decision making of moderate complexity. Counseling			
		and/or coordination of care with other physicians, other qualified health			
		care professionals, or agencies are provided consistent with the nature of the			
		problem(s) and the patient's and/or family's needs. Usually, the patient is			
		responding inadequately to therapy or has developed a minor complication.			
		Typically, 25 minutes are spent at the bedside and on the patient's hospital			
99225	0982, 0987	floor or unit.	01/01/11	03/18/20	

99226	0982, 0987	Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.	01/01/11	03/18/20	
99231	0657, 0987	Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is stable, recovering or improving. Typically, 15 minutes are spent at the bedside and on the patient's hospital floor or unit.	01/01/92	03/18/20	
99232	0657, 0987	Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.	01/01/92	03/18/20	
99233	0657, 0987	Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.	01/01/92	03/18/20	

99281	0450, 0451, 0452, 0456, 0459, 0981	Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self-limited or minor.	01/01/92	03/18/20	
99282	0450, 0451, 0452, 0456, 0459, 0981	Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity.	01/01/92	03/18/20	
99282	0439, 0981	Emergency department visit for the evaluation and management of a	01/01/92	03/18/20	
99283	0450, 0451, 0452, 0456, 0459, 0981	patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity.	01/01/92	03/18/20	
	0450, 0451, 0452, 0456,	Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: A detailed history; A detailed examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity, and require urgent evaluation by the physician, or other qualified health care professionals but			
99284	0459, 0981	do not pose an immediate significant threat to life or physiologic function.	01/01/92	03/18/20	

99285	0450, 0451, 0452, 0456, 0459, 0981	Emergency department visit for the evaluation and management of a patient, which requires these 3 key components within the constraints imposed by the urgency of the patient's clinical condition and/or mental status: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity and pose an immediate significant threat to life or physiologic function.	01/01/92	03/18/20	
	0360, 0361, 0450, 0452,				
	0456, 0459,				
	0510, 0512,				
	0513, 0514,				
	0515, 0516,				
	0517, 0519, 0520, 0526,				
	0529, 0681,	Critical care, evaluation and management of the critically ill or critically			
99291	0682	injured patient; first 30-74 minutes	01/01/92	03/18/20	
	0360, 0361,				
	0450, 0452,				
	0456, 0459,				
	0510, 0512,				
	0513, 0514,				
	0515, 0516, 0517, 0519,				
	0520, 0526,	Critical care, evaluation and management of the critically ill or critically			
	0529, 0681,	injured patient; each additional 30 minutes (List separately in addition to			
99292	0682	code for primary service)	01/01/92	03/18/20	
		Domiciliary or rest home visit for the evaluation and management of a new			
		patient, which requires these 3 key components: A problem focused history;			
		A problem focused examination; and Straightforward medical decision			
		making. Counseling and/or coordination of care with other physicians, other			
	0522 0525	qualified health care professionals, or agencies are provided consistent with			
	0522, 0525, 0527, 0657,	the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low severity. Typically, 20 minutes are			
99324	0969	spent with the patient and/or family or caregiver.	01/01/06	03/18/20	

99325	0522, 0525, 0527, 0657, 0969	Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient and/or family or caregiver.	01/01/06	03/18/20	
99326	0522, 0525, 0527, 0657, 0969	Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient and/or family or caregiver.	01/01/06	03/18/20	
99327	0522, 0525, 0527, 0657, 0969	Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity. Typically, 60 minutes are spent with the patient and/or family or caregiver.	01/01/06	03/18/20	
99328	0522, 0525, 0527, 0657, 0969	Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant new problem requiring immediate physician attention. Typically, 75 minutes are spent with the patient and/or family or caregiver.	01/01/06	03/18/20	

		Domiciliary or rest home visit for the evaluation and management of an			
		established patient, which requires at least 2 of these 3 key components: A			
		problem focused interval history; A problem focused examination;			
		Straightforward medical decision making. Counseling and/or coordination			
		of care with other physicians, other qualified health care professionals, or			
	0500 0505	agencies are provided consistent with the nature of the problem(s) and the			
	0522, 0525,	patient's and/or family's needs. Usually, the presenting problem(s) are self-			
00004	0527, 0657,	limited or minor. Typically, 15 minutes are spent with the patient and/or	01/01/06	00/10/00	
99334	0969	family or caregiver.	01/01/06	03/18/20	
		Domiciliary or rest home visit for the evaluation and management of an			
		established patient, which requires at least 2 of these 3 key components: An			
		expanded problem focused interval history; An expanded problem focused			
		examination; Medical decision making of low complexity. Counseling			
		and/or coordination of care with other physicians, other qualified health			
		care professionals, or agencies are provided consistent with the nature of the			
	0522, 0525,	problem(s) and the patient's and/or family's needs. Usually, the presenting			
	0527, 0657,	problem(s) are of low to moderate severity. Typically, 25 minutes are spent			
99335	0969	with the patient and/or family or caregiver.	01/01/06	03/18/20	
		Domiciliary or rest home visit for the evaluation and management of an			
		established patient, which requires at least 2 of these 3 key components: A			
		detailed interval history; A detailed examination; Medical decision making			
		of moderate complexity. Counseling and/or coordination of care with other			
		physicians, other qualified health care professionals, or agencies are			
		provided consistent with the nature of the problem(s) and the patient's			
	0522, 0525,	and/or family's needs. Usually, the presenting problem(s) are of moderate to			
	0527, 0657,	high severity. Typically, 40 minutes are spent with the patient and/or family			
99336	0969	or caregiver.	01/01/06	03/18/20	
		Domiciliary or rest home visit for the evaluation and management of an			
		established patient, which requires at least 2 of these 3 key components: A			
		comprehensive interval history; A comprehensive examination; Medical			
		decision making of moderate to high complexity. Counseling and/or			
		coordination of care with other physicians, other qualified health care			
		professionals, or agencies are provided consistent with the nature of the			
		problem(s) and the patient's and/or family's needs. Usually, the presenting			
		problem(s) are of moderate to high severity. The patient may be unstable or			
	0522, 0525,	may have developed a significant new problem requiring immediate			
	0527, 0657,	physician attention. Typically, 60 minutes are spent with the patient and/or			
99337	0969	family or caregiver.	01/01/06	03/18/20	

		Home visit for the evaluation and management of a new patient, which			
		requires these 3 key components: A problem focused history; A problem			
		focused examination; and Straightforward medical decision making.			
		Counseling and/or coordination of care with other physicians, other			
		qualified health care professionals, or agencies are provided consistent with			
		1 1			
	0522 0527	the nature of the problem(s) and the patient's and/or family's needs. Usually,			
00241	0522, 0527,	the presenting problem(s) are of low severity. Typically, 20 minutes are	01/01/02	02/19/20	
99341	0657, 0969	spent face-to-face with the patient and/or family.	01/01/92	03/18/20	
		Home visit for the evaluation and management of a new patient, which			
		requires these 3 key components: An expanded problem focused history;			
		An expanded problem focused examination; and Medical decision making			
		of low complexity. Counseling and/or coordination of care with other			
		physicians, other qualified health care professionals, or agencies are			
		provided consistent with the nature of the problem(s) and the patient's			
	0522 0527	and/or family's needs. Usually, the presenting problem(s) are of moderate			
99342	0522, 0527, 0657, 0969	severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.	01/01/92	03/18/20	
99342	0037, 0909	Home visit for the evaluation and management of a new patient, which	01/01/92	03/16/20	
		requires these 3 key components: A detailed history; A detailed			
		examination; and Medical decision making of moderate complexity.			
		Counseling and/or coordination of care with other physicians, other			
		qualified health care professionals, or agencies are provided consistent with			
		the nature of the problem(s) and the patient's and/or family's needs. Usually,			
	0522, 0527,	the presenting problem(s) are of moderate to high severity. Typically, 45			
99343	0657, 0969	minutes are spent face-to-face with the patient and/or family.	01/01/92	03/18/20	
77343	0037, 0909	Home visit for the evaluation and management of a new patient, which	01/01/92	03/16/20	
		requires these 3 key components: A comprehensive history; A			
		comprehensive examination; and Medical decision making of moderate			
		complexity. Counseling and/or coordination of care with other physicians,			
		other qualified health care professionals, or agencies are provided consistent			
		with the nature of the problem(s) and the patient's and/or family's needs.			
	0522, 0527,	Usually, the presenting problem(s) are of high severity. Typically, 60			
99344	0657, 0969	minutes are spent face-to-face with the patient and/or family.	01/01/98	03/18/20	
77377	10057,000	infinites are spent race-to-race with the patient and/or raining.	01/01/70	03/10/20	

		Home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant new problem			
	0522, 0527,	requiring immediate physician attention. Typically, 75 minutes are spent			
99345	0657, 0969	face-to-face with the patient and/or family.	01/01/98	03/18/20	
99347	0522, 0527, 0657, 0969	Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self-limited or minor. Typically, 15 minutes are spent face-to-face with the patient and/or family.	01/01/98	03/18/20	
77517	0027,0707	Home visit for the evaluation and management of an established patient,	01/01/90	02/10/20	
		which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination;			
		Medical decision making of low complexity. Counseling and/or			
		coordination of care with other physicians, other qualified health care			
		professionals, or agencies are provided consistent with the nature of the			
	0.500	problem(s) and the patient's and/or family's needs. Usually, the presenting			
00240	0522, 0527,	problem(s) are of low to moderate severity. Typically, 25 minutes are spent	01/01/00	00/10/20	
99348	0657, 0969	face-to-face with the patient and/or family.	01/01/98	03/18/20	
		Home visit for the evaluation and management of an established patient,			
		which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of moderate			
		complexity. Counseling and/or coordination of care with other physicians,			
		other qualified health care professionals, or agencies are provided consistent			
		with the nature of the problem(s) and the patient's and/or family's needs.			
	0522, 0527,	Usually, the presenting problem(s) are moderate to high severity. Typically,			
99349	0657, 0969	40 minutes are spent face-to-face with the patient and/or family.	01/01/98	03/18/20	

		Home visit for the evaluation and management of an established patient,			
		which requires at least 2 of these 3 key components: A comprehensive			
		interval history; A comprehensive examination; Medical decision making of			
		moderate to high complexity. Counseling and/or coordination of care with			
		other physicians, other qualified health care professionals, or agencies are			
		provided consistent with the nature of the problem(s) and the patient's			
		and/or family's needs. Usually, the presenting problem(s) are of moderate to			
		high severity. The patient may be unstable or may have developed a			
	0522, 0527,	significant new problem requiring immediate physician attention. Typically,			
99350	0657, 0969	60 minutes are spent face-to-face with the patient and/or family.	01/01/98	03/18/20	
	0450, 0510,				
	0511, 0512,				
	0513, 0514,				
	0515, 0516,	Medical team conference with interdisciplinary team of health care			
	0517, 0519,	professionals, patient and/or family not present, 30 minutes or more;			
99367	0520, 0526	participation by physician	01/01/08	03/18/20	
		Online digital evaluation and management service, for an established			
99421	0982	patient, for up to 7 days, cumulative time during the 7 days; 5–10 minutes	01/01/20	03/18/20	
		Online digital evaluation and management service, for an established			
99422	0982	patient, for up to 7 days cumulative time during the 7 days; 11–20 minutes	01/01/08	03/18/20	
		Online digital evaluation and management service, for an established			
		patient, for up to 7 days, cumulative time during the 7 days; 21 or more			
99423	0982	minutes	01/01/20	03/18/20	
		Telephone evaluation and management service by a physician or other			
		qualified health care professional who may report evaluation and			
	0780, 0960,	management services provided to an established patient, parent, or guardian			
	0969, 0981,	not originating from a related E/M service provided within the previous 7			
	0982, 0983,	days nor leading to an E/M service or procedure within the next 24 hours or			
99441	0987	soonest available appointment; 5-10 minutes of medical discussion	01/01/08	03/18/20	
		Telephone evaluation and management service by a physician or other			
	0.000	qualified health care professional who may report evaluation and			
	0780, 0960,	management services provided to an established patient, parent, or guardian			
	0969, 0981,	not originating from a related E/M service provided within the previous 7			
00//2	0982, 0983,	days nor leading to an E/M service or procedure within the next 24 hours or	0.1.10 : : 2.2	0045	
99442	0987, 0988	soonest available appointment; 11-20 minutes of medical discussion	01/01/08	03/18/20	

		Telephone evaluation and management service by a physician or other			
		qualified health care professional who may report evaluation and			
	0780, 0960,	management services provided to an established patient, parent, or guardian			
	0969, 0981,	not originating from a related E/M service provided within the previous 7			
	0982, 0983,	days nor leading to an E/M service or procedure within the next 24 hours or			
99443	0987, 0988	soonest available appointment; 21-30 minutes of medical discussion	01/01/15	03/18/20	
	0510, 0520,				
	0657, 0982,				
99499	0987	Unlisted evaluation and management service	01/01/92	03/18/20	
		Infectious disease (bacterial or viral respiratory tract infection), pathogen-			
		specific nucleic acid (DNA or RNA), 22 targets including severe acute			
		respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR,			
0202U	0310	nasopharyngeal swab, each pathogen reported as detected or not detected	05/20/20	05/20/20	
		Infectious disease (bacterial or viral respiratory tract infection), pathogen-			
		specific nucleic acid (DNA or RNA), 22 targets including severe acute			
		respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR,			
0223U	0310	nasopharyngeal swab, each pathogen reported as detected or not detected	06/25/20	06/25/20	
		Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)			
0224U	0310	(Coronavirus disease [COVID-19]), includes titer(s), when performed	06/25/20	06/25/20	
3		Infectious disease (bacterial or viral respiratory tract infection) pathogen-	3 3, 23, 23	0 0, 20, 20	
		specific DNA and RNA, 21 targets, including severe acute respiratory			
		syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique,			
		including multiplex reverse transcription for RNA targets, each analyte			
0225U	0310	reported as detected or not detected	08/10/20	08/10/20	
	1 2 2 2	Surrogate viral neutralization test (sVNT), severe acute respiratory	5 5. = 5. = 5	23.20.20	
		syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-			
0226U	0310	19]), ELISA, plasma, serum	08/10/20	08/10/20	
32200	1320	Infectious disease (viral respiratory tract infection), pathogen-specific RNA,	00, 10, 20	00,10,20	
		3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2],			
		influenza A, influenza B), upper respiratory specimen, each pathogen			
0240U	0310	reported as detected or not detected	10/06/20	10/06/20	
02100	3310	Infectious disease (viral respiratory tract infection), pathogen-specific RNA,	10/00/20	10,00,20	
		4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2],			
		influenza A, influenza B, respiratory syncytial virus [RSV]), upper			
0241U	0310	respiratory specimen, each pathogen reported as detected or not detected	10/06/20	10/06/20	
U241U	0310	respiratory specimen, each pathogen reported as detected of not detected	10/00/20	10/00/20	

		Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease			
		[covid-19]), any specimen source, is effective for services provided on or			
C9803	0300	after March 1, 2020	03/01/20	03/01/20	
		Payment for communication technology-based services for 5 minutes or			
		more of a virtual (non-face-to-face) communication between an rural health			
		clinic (RHC) or federally qualified health center (FQHC) practitioner and			
		RHC or FQHC patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an RHC or FQHC practitioner, occurring			
G0071	0529	in lieu of an office visit; RHC or FQHC only	01/01/19	03/18/20	
30071	0456, 0510,	in near of an office visit, rate of 1 gife only	01/01/19	03/10/20	
	0511, 0512,				
	0513, 0514,				
	0515, 0516,				
	0517, 0519,				
G0.4.5	0520, 0526,	Hospital outpatient clinic visit for assessment and management of a patient;	0.1.10.1.11.1	0.0 (4.0 (0.0	
G0463	0529	This is the code that hospitals use instead of E&M codes 99211 - 99215	01/01/14	03/18/20	
		Remote evaluation of recorded video and/or images submitted by an			
		established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a			
		related E/M service provided within the previous 7 days nor leading to an			
		E/M service or procedure within the next 24 hours or soonest available			
G2010	0988	appointment	01/01/19	03/18/20	12/31/20
		Brief communication technology-based service, e.g., virtual check-in, by a			
		physician or other qualified health care professional who can report			
		evaluation and management services, provided to an established patient, not			
		originating from a related E/M service provided within the previous 7 days			
G2012	0988	nor leading to an E/M service or procedure within the next 24 hours or	01/01/19	03/18/20	12/31/20
G2012	0361, 0450,	soonest available appointment; 5-10 minutes of medical discussion	01/01/19	03/18/20	12/31/20
	0501, 0430, 0510, 0510,	Specimen collection for Severe Acute Respiratory Syndrome Coronavirus 2			
G2023	0510, 0313, 0521, 0761	(SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source	03/01/20	03/18/20	
32020	0361, 0450,	Specimen collection for Severe Acute Respiratory Syndrome Coronavirus 2	30, 31, 23	55, 15, 25	
	0510, 0519,	(SARS-CoV-2) (Coronavirus disease [COVID-19]) from an individual in a			
G2024	0521, 0761	SNF or by a laboratory on behalf of a HHA, any specimen source	03/01/20	03/18/20	
		Qualified non-physician healthcare professional online assessment and			
22. 5. 1	00.00	management, for an established patient, for up to seven days, cumulative	0.4 (0.1.15.0	00// 0/2	10/01/20
G2061	0969	time during the 7 days; 5–10 minutes	01/01/20	03/18/20	12/31/20

		Qualified non-physician healthcare professional online assessment and			
		management service, for an established patient, for up to seven days,			
G2062	0969	cumulative time during the 7 days; 11–20 minutes	01/01/20	03/18/20	12/31/20
		Qualified non-physician qualified healthcare professional assessment and			
		management service, for an established patient, for up to seven days,			
G2063	0969	cumulative time during the 7 days; 21 or more minutes	01/01/20	03/18/20	12/31/20
		Remote assessment of recorded video and/or images submitted by an			
		established patient (e.g., store and forward), including interpretation with			
		follow-up with the patient within 24 business hours, not originating from a			
	0960, 0982,	related service provided within the previous 7 days nor leading to a service			
G2250	0983, 0988	or procedure within the next 24 hours or soonest available appointment	01/01/21	01/01/21	
		Brief communication technology-based service, e.g. virtual check-in, by a			
		qualified health care professional who cannot report evaluation and			
		management services, provided to an established patient, not originating			
		from a related service provided within the previous 7 days nor leading to a			
	0960, 0982,	service or procedure within the next 24 hours or soonest available			
G2251	0983, 0988	appointment; 5-10 minutes of clinical discussion	01/01/21	01/01/21	
T1015	0521	Clinic visit/encounter, all-inclusive	01/01/02	03/18/20	
		The 2019-Novel Coronavirus (2019-nCoV or COVID-19) Real-Time RT-			
		PCR Diagnostic Panel is a molecular in vitro diagnostic test intended for			
		presumptive qualitative detection of nucleic acid from COVID-19 in both			
		upper and lower respiratory tract specimens (e.g., naso- or oropharyngeal			
		swabs, sputum, aspirates, etc.) collected from patients that meet Centers for			
U0002	0300, 0310	Disease Control and Prevention (CDC) testing criteria.	02/04/20	03/18/20	
		Infectious agent detection by nucleic acid (DNA or RNA); severe acute			
		respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
******	0200 0210	[COVID-19]), amplified probe technique, making use of high throughput	0.4/4.4/2.0	0.4/4.4/2.0	
U0003	0300, 0310	technologies as described by CMS-2020-01-R.	04/14/20	04/14/20	
		2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any			
		technique, multiple types or subtypes (includes all targets), non-CDC,			
T10004	0200 0210	making use of high throughput technologies as described by CMS-2020-01-	0.4/1.4/20	0.4/1.4/20	
U0004	0300, 0310	R.	04/14/20	04/14/20	
		Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute			
		Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
		[COVID-19]), amplified probe technique, CDC or non-CDC, making use of			
		high throughput technologies, completed within 2 calendar days from date			
110005	0206 0210	of specimen collection (list separately in addition to either HCPCS code	01/01/21	01/01/21	
U0005	0306, 0310	U0003 or U0004) as described by CMS-2020-01-R2	01/01/21	01/01/21	

COVID-19 Treatment Codes

COVID-19 Diagnosis Codes (COVID-19 treatment procedure codes are billable for Uninsured Individuals with one or more of the diagnosis codes contained in this chart.)					
ICD-10 Diagnosis Code	Code Description	Code Effective Date			
U07.1	COVID-19; Use additional code to identify pneumonia or other manifestations	04/01/20			
U09.9	Post COVID-19 condition, unspecified	04/01/22			
J12.81	pneumonia due to SARS-associated coronavirus	10/01/15			
J12.82	Pneumonia due to coronavirus disease 2019; "Pneumonia due to 2019 novel coronavirus (SARS-CoV-2); Pneumonia due to COVID-19"; Code first COVID-19 (U07.1)	01/01/21			
Z86.16	Personal history of COVID-19	01/01/21			

COVI	COVID-19 Monoclonal Antibody Treatment						
Code	Revenue Codes	Code Description	MaineCare Effective Date(s)	Uninsured Coverage Effective Date			
Eli Lilly	EUA Monoclonal Antib	ody COVID-19 Infusion Treatment					
Q0239	0636	Injection, bamlanivimab-xxxx, 700 mg	11/10/21- 04/16/21*	03/11/21 - 04/16/21*			
M0239	0260, 0771	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	11/10/21- 04/16/21*	03/11/21 - 04/16/21*			
Q0245	0636	Injection, bamlanivimab and etesevimab, 2100 mg	02/09/21- 01/24/22**	03/11/21- 01/24/22**			
M0245	0260, 0771	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	02/09/21- 01/24/22**	03/11/21- 01/24/22**			
M0246	0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940,	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency.	05/06/21- 01/24/22**	05/06/21- 01/24/22**			
Q0222	0636	Injection, bebtelovimab, 175 mg	02/11/22	[02/11/22]			

M0222	0260, 0771	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	02/11/22	[02/11/22]
M0223	0260, 0771	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	02/11/22	[02/11/22]
Regener	on EUA Monoclonal A	Antibody COVID-19 Infusion Treatment		
Q0240	0636	Injection, casirivimab and imdevimab, 600 mg	7/30/2021- 01/24/22**	07/30/21- 01/24/22**
Q0243	0636	Injection, casirivimab and imdevimab, 2400 mg	11/21/20- 01/24/22**	03/11/21- 01/24/22**
Q0244	0636	Injection, casirivimab and imdevimab, 1200 mg	06/03/21- 01/24/22**	06/03/21- 01/24/22**
M0240	0260, 0636	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	07/30/21- 01/24/22**	07/30/21- 01/24/22**
M0241	0260, 0636	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	07/30/21- 01/24/22**	07/30/21- 01/24/22**
M0243	0260, 0771	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring	11/21/20- 01/24/22**	03/11/21- 01/24/22**
M0244	0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940,	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency.	05/06/21- 01/24/22**	05/06/21- 01/24/22**
GlaxoSn	nithKline EUA Monoc	clonal Antibody COVID-19 Infusion Treatment		
Q0247	0636	Injection, sotrovimab, 500 mg	05/26/21- 02/25/22**	05/26/21- 02/25/22**
M0247	0260	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	05/26/21- 02/25/22**	05/26/21- 02/25/22**
M0248	0260	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that	05/26/21- 02/25/22**	05/26/21- 02/25/22**

		has been made provider-based to the hospital during the covid-19 public health emergency		
Genente	ch EUA Monoclonal Anti	body COVID-19 Infusion Treatment		
Q0249	0636	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	06/24/21	06/24/21
M0249	0260	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	06/24/21	06/24/21
M0250	0260	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	06/24/21	06/24/21
AstraZe	eneca EUA Monoclonal A	Antibody COVID-19 Infusion Treatment		
Q0220	0636	Tixagev and cilgav, 300 mg	12/08/21	12/08/21
M0220	0771	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	12/08/21	12/08/21
M0221	0771	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	12/08/2021	12/08/2021

*Effective dates ended with the <u>FDA's revocation</u> of the EUA for monoclonal antibody treatment with bamlanivimab alone.

**Effective dates ended with the FDA's ending of the EUA for this monoclonal antibody treatment nationally or regionally.

[]Coverage limited to Government Supply

COVID	COVID-19 Treatment Covered Services for Uninsured Individuals					
CPT & HCPC			Uninsured Benefit Code	MaineCare End		
Codes	Revenue Codes	Code Description	Effective Date	Date		
		Anesthesia for all procedures on the larynx and trachea in children younger				
00326	0370, 0963, 0964	than 1 year of age	03/11/21			
		Anesthesia for closed chest procedures; (including bronchoscopy) not				
00520	0370, 0963, 0964	otherwise specified	03/11/21			
00524	0370, 0963, 0964	Anesthesia for closed chest procedures; pneumocentesis	03/11/21			
		Anesthesia for closed chest procedures; mediastinoscopy and diagnostic				
00529	0370, 0963, 0964	thoracoscopy utilizing 1 lung ventilation	03/11/21			
00532	0370, 0963, 0964	Anesthesia for access to central venous circulation	03/11/21			
		Anesthesia for thoracotomy procedures involving lungs, pleura, diaphragm,				
00540	0370, 0963, 0964	and mediastinum (including surgical thoracoscopy); not otherwise specified	03/11/21			
01922	0370, 0963, 0964	Anesthesia for non-invasive imaging or radiation therapy	03/11/21			
	0360, 0361, 0450,					
	0490, 0510, 0514,					
	0515, 0516, 0517,					
	0519, 0520, 0521,					
10160	0529	Puncture aspiration of abscess, hematoma, bulla, or cyst	03/11/21			
	0360, 0361, 0410,					
	0412, 0419, 0450,					
	0490, 0510, 0514,					
	0515, 0516, 0517,					
31500	0519, 0761	Intubation, endotracheal, emergency procedure	03/11/21			
	0360, 0361, 0410,					
	0412, 0419, 0450,					
	0490, 0510, 0514,					
	0515, 0516, 0517,					
31502	0519, 0761	Tracheotomy tube change prior to establishment of fistula tract	03/11/21			
	0360, 0361, 0450,					
	0490, 0510, 0516,					
31505	0517, 0519, 0761	Laryngoscopy, indirect; diagnostic (separate procedure)	03/11/21			

	0360, 0361, 0450,		
	0490, 0510, 0516,	Laryngoscopy direct, with or without tracheoscopy; diagnostic, except	
31525	0517, 0519, 0761	newborn	03/11/21
31323	0360, 0361, 0450,	newborn	03/11/21
	0490, 0510, 0516,	Laryngoscopy direct, with or without tracheoscopy; diagnostic, with	
31526	0517, 0519, 0761	operating microscope or telescope	03/11/21
31320	0360, 0361, 0450,	operating interescope of terescope	03/11/21
	0490, 0510, 0516,	Laryngoscopy direct, with or without tracheoscopy; with insertion of	
31527	0517, 0519, 0761	obturator	03/11/21
31327	0360, 0361, 0450,	Obturutor	03/11/21
	0490, 0510, 0516,		
31528	0517, 0519, 0761	Laryngoscopy direct, with or without tracheoscopy; with dilation, initial	03/11/21
21220	0360, 0361, 0450,	Zarjingoseopj uneet, with or without trachesseopj, with unation, initial	00/11/21
	0490, 0510, 0516,	Laryngoscopy direct, with or without tracheoscopy; with dilation,	
31529	0517, 0519, 0761	subsequent	03/11/21
0.10.17	0360, 0361, 0450,		
	0490, 0510, 0516,		
31535	0517, 0519, 0761	Laryngoscopy, direct, operative, with biopsy	03/11/21
	0360, 0361, 0450,	——————————————————————————————————————	
	0490, 0510, 0516,		
31600	0517, 0519, 0761	Tracheostomy, planned (separate procedure)	03/11/21
	0360, 0361, 0450,		
	0490, 0510, 0516,		
31601	0517, 0519, 0761	Tracheostomy, planned (separate procedure); younger than 2 years	03/11/21
	0360, 0361, 0450,		
	0490, 0510, 0516,		
31603	0517, 0519, 0761	Tracheostomy, emergency procedure; transtracheal	03/11/21
	0360, 0361, 0450,		
	0490, 0510, 0516,		
31605	0517, 0519, 0761	Tracheostomy, emergency procedure; cricothyroid membrane	03/11/21
	0360, 0361, 0450,		
	0490, 0510, 0519,		
31720	0761	Catheter aspiration (separate procedure); nasotracheal	03/11/21
		Catheter aspiration (separate procedure); tracheobronchial with fiberscope,	
31725	0360	bedside	03/11/21
	0360, 0361, 0450,		
	0490, 0510, 0516,	Transtracheal (percutaneous) introduction of needle wire dilator/stent or	
31730	0517, 0519, 0761	indwelling tube for oxygen therapy	03/11/21

		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
33946	0360	(ECLS) provided by physician; initiation, veno-venous	03/11/21
		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
33947	0360	(ECLS) provided by physician; initiation, veno-arterial	03/11/21
		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
33948	0360	(ECLS) provided by physician; daily management, each day, veno-venous	03/11/21
		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
33949	0360	(ECLS) provided by physician; daily management, each day, veno-arterial	03/11/21
		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
		(ECLS) provided by physician; insertion of peripheral (arterial and/or	
		venous) cannula(e), percutaneous, birth through 5 years of age (includes	
33951	0360	fluoroscopic guidance, when performed)	03/11/21
		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
		(ECLS) provided by physician; insertion of peripheral (arterial and/or	
		venous) cannula(e), percutaneous, 6 years and older (includes fluoroscopic	
33952	0360	guidance, when performed)	03/11/21
		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
		(ECLS) provided by physician; insertion of peripheral (arterial and/or	
33953	0360	venous) cannula(e), open, birth through 5 years of age	03/11/21
		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
		(ECLS) provided by physician; insertion of peripheral (arterial and/or	
33954	0360	venous) cannula(e), open, 6 years and older	03/11/21
		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
		(ECLS) provided by physician; insertion of central cannula(e) by sternotomy	
33955	0360	or thoracotomy, birth through 5 years of age	03/11/21
		Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support	
		(ECLS) provided by physician; insertion of central cannula(e) by sternotomy	
33956	0360	or thoracotomy, 6 years and older	03/11/21
		Insertion of left heart vent by thoracic incision (eg, sternotomy,	
33988	0360	thoracotomy) for ECMO/ECLS	03/11/21
	0320, 0329, 0340,		
	0341, 0342, 0349,		
	0350, 0352, 0359,		
	0360, 0361, 0409,		
	0450, 0490, 0510,		
	0514, 0515, 0516,		
36014	0517, 0519	Selective catheter placement, left or right pulmonary artery	03/11/21

	0220 0220 0240			
	0320, 0329, 0340,			
	0341, 0342, 0349,			
	0350, 0352, 0359,			
	0360, 0361, 0409,			
	0450, 0490, 0510,			
	0514, 0515, 0516,			
36015	0517, 0519	Selective catheter placement, segmental or subsegmental pulmonary artery	03/11/21	
	0320, 0329, 0340,			
	0341, 0342, 0349,			
	0350, 0352, 0359,			
	0360, 0361, 0409,			
	0450, 0490, 0510,			
	0514, 0515, 0516,	Selective catheter placement, arterial system; each first order thoracic or		
36215	0517, 0519	brachiocephalic branch, within a vascular family	03/11/21	
	0320, 0329, 0340,			
	0341, 0342, 0349,			
	0350, 0352, 0359,			
	0360, 0361, 0409,			
	0450, 0490, 0510,			
	0514, 0515, 0516,	Selective catheter placement, arterial system; initial second order thoracic or		
36216	0517, 0519	brachiocephalic branch, within a vascular family	03/11/21	
30210	0320, 0329, 0340,	bracinocephane branen, within a vascular fainity	03/11/21	
	0341, 0342, 0349,			
	0350, 0352, 0359,			
	0360, 0361, 0409,			
	0450, 0490, 0510,			
26217	0514, 0515, 0516,	Selective catheter placement, arterial system; initial third order or more	00/11/01	
36217	0517, 0519	selective thoracic or brachiocephalic branch, within a vascular family	03/11/21	
	0320, 0329, 0340,			
	0341, 0342, 0349,			
	0350, 0352, 0359,			
	0360, 0361, 0409,	Selective catheter placement, arterial system; additional second order, third		
	0450, 0490, 0510,	order, and beyond, thoracic or brachiocephalic branch, within a vascular		
	0514, 0515, 0516,	family (List in addition to code for initial second or third order vessel as		
36218	0517, 0519	appropriate)	03/11/21	
	0360, 0361, 0450,			
	0490, 0510, 0514,	Venipuncture, younger than age 3 years, necessitating the skill of a physician		
	0515, 0516, 0517,	or other qualified health care professional, not to be used for routine		
36400	0519, 0521, 0761	venipuncture; femoral or jugular vein	03/11/21	

	0360, 0361, 0450,		
	0490, 0510, 0514,	Venipuncture, age 3 years or older, necessitating the skill of a physician or	
	0515, 0516, 0517,	other qualified health care professional (separate procedure), for diagnostic	
36410	0519, 0521, 0761	or therapeutic purposes (not to be used for routine venipuncture)	03/11/21
	0300, 0360, 0361,		
36415	0450, 0510, 0519	Collection of venous blood by venipuncture	03/11/21
	0300, 0360, 0361,		
	0450, 0510, 0514,		
36416	0515	Collection of capillary blood specimen (eg, finger, heel, ear stick)	03/11/21
	0360, 0361, 0450,		
	0490, 0510, 0514,		
	0515, 0516, 0517,		
36420	0519, 0761	Venipuncture, cutdown; younger than age 1 year	03/11/21
	0360, 0361, 0450,		
	0490, 0510, 0514,		
	0515, 0516, 0517,		
36425	0519, 0761	Venipuncture, cutdown; age 1 or over	03/11/21
	0360, 0361, 0450,		
	0452, 0456, 0459,		
	0490, 0510, 0514,		
	0515, 0516, 0517,	Insertion of non-tunneled centrally inserted central venous catheter; younger	
36555	0519, 0761	than 5 years of age	03/11/21
	0360, 0361, 0450,		
	0452, 0456, 0459,		
	0490, 0510, 0514,		
	0515, 0516, 0517,	Insertion of tunneled centrally inserted central venous catheter, without	
36557	0519, 0761	subcutaneous port or pump; younger than 5 years of age	03/11/21
	0360, 0361, 0450,		
	0452, 0456, 0459,		
	0490, 0510, 0514,	Insertion of peripherally inserted central venous catheter (PICC), without	
	0515, 0516, 0517,	subcutaneous port or pump, without imaging guidance; younger than 5 years	
36568	0519, 0761	of age	03/11/21
	0320, 0360, 0361,	Insertion of peripherally inserted central venous catheter (PICC), without	
	0450, 0510, 0515,	subcutaneous port or pump, including all imaging guidance, image	
	0516, 0516, 0517,	documentation, and all associated radiological supervision and interpretation	
36572	0519, 0761	required to perform the insertion; younger than 5 years of age	03/11/21

	0320, 0360, 0361,	Insertion of peripherally inserted central venous catheter (PICC), without		
	0450, 0510, 0515,	subcutaneous port or pump, including all imaging guidance, image		
	0516, 0516, 0517,	documentation, and all associated radiological supervision and interpretation		
36573	0519, 0761	required to perform the insertion; age 5 years or older	03/11/21	
20272	0320, 0329, 0340,	required to perform the insertion, age by ears of order	05/11/21	
	0341, 0342, 0349,			
	0350, 0351, 0352,			
	0359, 0360, 0361,			
	0450, 0490, 0510,			
	0514, 0515, 0516,			
62270	0517, 0519	Spinal puncture, lumbar, diagnostic	03/11/21	
	0320, 0350, 0360,			
	0361, 0450, 0510,			
	0519, 0520, 0529,			
62328	0761	Spinal puncture, lumbar, diagnostic; with fluoroscopic or CT guidance	03/11/21	
70450	0350, 0351, 0359	Computed tomography, head or brain; without contrast material	03/11/21	
70460	0350, 0351, 0359	Computed tomography, head or brain; with contrast material(s)	03/11/21	
		Computed tomography, head or brain; without contrast material, followed by		
70470	0350, 0351, 0359	contrast material(s) and further sections	03/11/21	
		Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without		
70543	0610, 0614	contrast material(s), followed by contrast material(s) and further sequences	03/11/21	
		Magnetic resonance (eg, proton) imaging, brain (including brain stem);		
70551	0610, 0611	without contrast material	03/11/21	
		Magnetic resonance (eg, proton) imaging, brain (including brain stem); with		
70552	0610, 0611	contrast material(s)	03/11/21	
		Magnetic resonance (eg, proton) imaging, brain (including brain stem);		
		without contrast material, followed by contrast material(s) and further		
70553	0610, 0611	sequences	03/11/21	
71047	0320, 0324	Radiologic examination, chest; 3 views	03/11/21	
71048	0320, 0324	Radiologic examination, chest; 4 or more views	03/11/21	
71260	0350, 0352, 0359	Computed tomography, thorax, diagnostic; with contrast material(s)	03/11/21	
		Computed tomography, thorax, diagnostic; without contrast material,		
71270	0350, 0352, 0359	followed by contrast material(s) and further sections	03/11/21	
		Computed tomographic angiography, chest (noncoronary), with contrast		
	0070 0070 0075	material(s), including noncontrast images, if performed, and image	00/11/01	
71275	0350, 0352, 0359	postprocessing	03/11/21	
71550	0610 0614	Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar	02/11/21	
71550	0610, 0614	and mediastinal lymphadenopathy); without contrast material(s)	03/11/21	

		Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar		
71551	0610, 0614	and mediastinal lymphadenopathy); with contrast material(s)	03/11/21	
		Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar		
		and mediastinal lymphadenopathy); without contrast material(s), followed by		
71552	0610, 0614	contrast material(s) and further sequences	03/11/21	
		Magnetic resonance angiography, chest (excluding myocardium), with or		
71555	0610, 0618	without contrast material(s)	03/11/21	
		Myelography, 2 or more regions (eg, lumbar/thoracic, cervical/thoracic,		
		lumbar/cervical, lumbar/thoracic/cervical), radiological supervision and		
72270	0320, 0329	interpretation	03/11/21	
		Computed tomographic angiography, abdomen, with contrast material(s),		
74175	0350, 0352, 0359	including noncontrast images, if performed, and image postprocessing	03/11/21	
74176	0350, 0352, 0359	Computed tomography, abdomen and pelvis; without contrast material	03/11/21	
74177	0350, 0352, 0359	Computed tomography, abdomen and pelvis; with contrast material(s)	03/11/21	
		Computed tomography, abdomen and pelvis; without contrast material in		
		one or both body regions, followed by contrast material(s) and further		
74178	0350, 0352, 0359	sections in one or both body regions	03/11/21	
	0350, 0351, 0352,			
76380	0359	Computed tomography, limited or localized follow-up study	03/11/21	
		Ultrasound, abdominal, real time with image documentation; limited (eg,		
76705	0402	single organ, quadrant, follow-up)	03/11/21	
		Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image		
76770	0402	documentation; complete	03/11/21	
		Fluoroscopic guidance for central venous access device placement,		
		replacement (catheter only or complete), or removal (includes fluoroscopic		
		guidance for vascular access and catheter manipulation, any necessary		
		contrast injections through access site or catheter with related venography		
		radiologic supervision and interpretation, and radiographic documentation of		
		final catheter position) (List separately in addition to code for primary		
77001	0320, 0329, 0402	procedure)	03/11/21	
		Myocardial perfusion imaging, tomographic (SPECT) (including attenuation		
		correction, qualitative or quantitative wall motion, ejection fraction by first		
		pass or gated technique, additional quantification, when performed); single		
78451	0340, 0341, 0349	study, at rest or stress (exercise or pharmacologic)	03/11/21	

		Myocardial perfusion imaging, tomographic (SPECT) (including attenuation		
		correction, qualitative or quantitative wall motion, ejection fraction by first		
		pass or gated technique, additional quantification, when performed); multiple		
		studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution		
78452	0340, 0341, 0349	and/or rest reinjection	03/11/21	
		Myocardial perfusion imaging, planar (including qualitative or quantitative		
		wall motion, ejection fraction by first pass or gated technique, additional		
		quantification, when performed); single study, at rest or stress (exercise or		
78453	0340, 0341, 0349	pharmacologic)	03/11/21	
		Myocardial perfusion imaging, planar (including qualitative or quantitative		
		wall motion, ejection fraction by first pass or gated technique, additional		
		quantification, when performed); multiple studies, at rest and/or stress		
78454	0340, 0341, 0349	(exercise or pharmacologic) and/or redistribution and/or rest reinjection	03/11/21	
78579	0340, 0341, 0349	Pulmonary ventilation imaging (eg, aerosol or gas)	03/11/21	
78580	0340, 0341, 0349	Pulmonary perfusion imaging (eg, particulate)	03/11/21	
78582	0340, 0341, 0349	Pulmonary ventilation (eg, aerosol or gas) and perfusion imaging	03/11/21	
		Quantitative differential pulmonary perfusion, including imaging when		
78597	0340, 0341, 0349	performed	03/11/21	
		Quantitative differential pulmonary perfusion and ventilation (eg, aerosol or		
78598	0340, 0341, 0349	gas), including imaging when performed	03/11/21	
		General health panel This panel must include the following: Comprehensive		
		metabolic panel (80053) Blood count, complete (CBC), automated and		
		automated differential WBC count (85025 or 85027 and 85004) OR Blood		
		count, complete (CBC), automated (85027) and appropriate manual		
		differential WBC count (85007 or 85009) Thyroid stimulating hormone		
80050	0300, 0301, 0309	(TSH) (84443)	03/11/21	
80198	0300, 0301, 0309	Theophylline	03/11/21	
		Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,		
		ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any		
81000	0300, 0307	number of these constituents; non-automated, with microscopy	03/11/21	
		Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,		
		ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any		
81001	0300, 0307	number of these constituents; automated, with microscopy	03/11/21	
		Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,		
		ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any		
81002	0300, 0307	number of these constituents; non-automated, without microscopy	03/11/21	

01002		Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,	
01002 020		ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any	
81003 030	00, 0307	number of these constituents; automated, without microscopy	03/11/21
81005 030	00, 0307	Urinalysis; qualitative or semiquantitative, except immunoassays	03/11/21
81007 030	00, 0307	Urinalysis; bacteriuria screen, except by culture or dipstick	03/11/21
81015 030	00, 0307	Urinalysis; microscopic only	03/11/21
82271 030	00, 0301, 0309	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; other sources	03/11/21
		Blood, occult, by fecal hemoglobin determination by immunoassay,	
82274 030	00, 0301, 0309	qualitative, feces, 1-3 simultaneous determinations	03/11/21
82595 030	00, 0301, 0309	Cryoglobulin, qualitative or semi-quantitative (eg, cryocrit)	03/11/21
82800 030	00, 0301, 0309	Gases, blood, pH only	03/11/21
		Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including	
82803 030	00, 0301, 0309	calculated O2 saturation)	03/11/21
		Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including	
		calculated O2 saturation); with O2 saturation, by direct measurement, except	
82805 030	00, 0301, 0309	pulse oximetry	03/11/21
		Gases, blood, O2 saturation only, by direct measurement, except pulse	
82810 030	00, 0301, 0309	oximetry	03/11/21
02020	00 0201 0200	Hemoglobin-oxygen affinity (pO2 for 50% hemoglobin saturation with	00/11/01
	00, 0301, 0309	oxygen)	03/11/21
	00, 0301, 0309,		02/11/01
82947 077		Glucose; quantitative, blood (except reagent strip)	03/11/21
82948 030	00, 0301, 0309	Glucose; blood, reagent strip	03/11/21
92062 026	00 0201 0200	Glucose, blood by glucose monitoring device(s) cleared by the FDA	02/11/21
	00, 0301, 0309	specifically for home use	03/11/21
	00, 0301, 0309	Protein, total, except by refractometry; urine	03/11/21
84165 030	00, 0301, 0309	Protein; electrophoretic fractionation and quantitation, serum Protein; electrophoretic fractionation and quantitation, other fluids with	03/11/21
84166 030	00, 0301, 0309	Protein; electrophoretic fractionation and quantitation, other fluids with concentration (eg, urine, CSF)	03/11/21
04100 030	00, 0301, 0309	Protein; Western Blot, with interpretation and report, blood or other body	03/11/21
84181 030	00, 0301, 0309	fluid	03/11/21
	00, 0301, 0309	Thyroxine; total	03/11/21
	00, 0301, 0309	Thyroxine; free	03/11/21
	00, 0301, 0309	Thyroid stimulating hormone (TSH)	03/11/21
01443	00, 0301, 0307	Thyroid hormone (T3 or T4) uptake or thyroid hormone binding ratio	03/11/21
84479 030	00, 0301, 0309	(THBR)	03/11/21
	00, 0301, 0309	Triiodothyronine T3; free	03/11/21
	00, 0301, 0309	Triiodothyronine T3; reverse	03/11/21

85002	0300, 0305, 0309	Bleeding time	03/11/21
85004	0300, 0305, 0309	Blood count; automated differential WBC count	03/11/21
		Blood count; blood smear, microscopic examination with manual differential	
85007	0300, 0305, 0309	WBC count	03/11/21
		Blood count; blood smear, microscopic examination without manual	
85008	0300, 0305, 0309	differential WBC count	03/11/21
85009	0300, 0305, 0309	Blood count; manual differential WBC count, buffy coat	03/11/21
85014	0300, 0305, 0309	Blood count; hematocrit (Hct)	03/11/21
		Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and	
85027	0300, 0305, 0309	platelet count)	03/11/21
85032	0300, 0305, 0309	Blood count; manual cell count (erythrocyte, leukocyte, or platelet) each	03/11/21
85041	0300, 0305, 0309	Blood count; red blood cell (RBC), automated	03/11/21
85048	0300, 0305, 0309	Blood count; leukocyte (WBC), automated	03/11/21
		Fibrin degradation products, D-dimer; ultrasensitive (eg, for evaluation for	
85380	0300, 0305, 0309	venous thromboembolism), qualitative or semiquantitative	03/11/21
85651	0300, 0305, 0309	Sedimentation rate, erythrocyte; non-automated	03/11/21
85652	0300, 0305, 0309	Sedimentation rate, erythrocyte; automated	03/11/21
85730	0300, 0305, 0309	Thromboplastin time, partial (PTT); plasma or whole blood	03/11/21
86140	0300, 0302, 0309	C-reactive protein	03/11/21
86689	0300, 0302, 0309	Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)	03/11/21
86701	0300, 0302, 0309	Antibody; HIV-1	03/11/21
86702	0300, 0302, 0309	Antibody; HIV-2	03/11/21
86703	0300, 0302, 0309	Antibody; HIV-1 and HIV-2, single result	03/11/21
86850	0300, 0302, 0309	Antibody screen, RBC, each serum technique	03/11/21
86860	0300, 0302, 0309	Antibody elution (RBC), each elution	03/11/21
		Antibody identification, RBC antibodies, each panel for each serum	
86870	0300, 0302, 0309	technique	03/11/21
		Antihuman globulin test (Coombs test); indirect, qualitative, each reagent	
86885	0300, 0302, 0309	red cell	03/11/21
86886	0300, 0302, 0309	Antihuman globulin test (Coombs test); indirect, each antibody titer	03/11/21
86900	0300, 0309, 0390	Blood typing, serologic; ABO	03/11/21
86901	0300, 0309, 0390	Blood typing, serologic; Rh (D)	03/11/21
		Blood typing, serologic; antigen testing of donor blood using reagent serum,	
86902	0300, 0309, 0390	each antigen test	03/11/21
0.5004	0000 0000 0000	Blood typing, serologic; antigen screening for compatible unit using patient	
86904	0300, 0309, 0390	serum, per unit screened	03/11/21
86905	0300, 0309, 0390	Blood typing, serologic; RBC antigens, other than ABO or Rh (D), each	03/11/21
86906	0300, 0309, 0390	Blood typing, serologic; Rh phenotyping, complete	03/11/21

86920	0300, 0309, 0390	Compatibility test each unit; immediate spin technique	03/11/21
86921	0300, 0309, 0390	Compatibility test each unit; incubation technique	03/11/21
86922	0300, 0309, 0390	Compatibility test each unit; antiglobulin technique	03/11/21
86923	0300, 0309, 0390	Compatibility test each unit; electronic	03/11/21
86945	0300, 0309, 0390	Irradiation of blood product, each unit	03/11/21
86950	0300, 0309	Leukocyte transfusion	03/11/21
		Volume reduction of blood or blood product (eg, red blood cells or platelets),	
86960	0300, 0309, 0390	each unit	03/11/21
		Pretreatment of RBCs for use in RBC antibody detection, identification,	
86970	0300, 0309, 0390	and/or compatibility testing; incubation with chemical agents or drugs, each	03/11/21
		Pretreatment of RBCs for use in RBC antibody detection, identification,	
86971	0300, 0309, 0390	and/or compatibility testing; incubation with enzymes, each	03/11/21
		Pretreatment of RBCs for use in RBC antibody detection, identification,	
86972	0300, 0309, 0390	and/or compatibility testing; by density gradient separation	03/11/21
		Pretreatment of serum for use in RBC antibody identification; incubation	
86975	0300, 0302, 0309	with drugs, each	03/11/21
	0300, 0302, 0309,		
86976	0390	Pretreatment of serum for use in RBC antibody identification; by dilution	03/11/21
	0300, 0302, 0309,	Pretreatment of serum for use in RBC antibody identification; incubation	
86977	0390	with inhibitors, each	03/11/21
		Pretreatment of serum for use in RBC antibody identification; by differential	
	0300, 0302, 0309,	red cell absorption using patient RBCs or RBCs of known phenotype, each	
86978	0390	absorption	03/11/21
		Culture, bacterial; any other source except urine, blood or stool, aerobic,	
87070	0300, 0306, 0309	with isolation and presumptive identification of isolates	03/11/21
		Culture, bacterial; quantitative, aerobic with isolation and presumptive	
87071	0300, 0306, 0309	identification of isolates, any source except urine, blood or stool	03/11/21
		Culture, bacterial; quantitative, anaerobic with isolation and presumptive	
87073	0300, 0306, 0309	identification of isolates, any source except urine, blood or stool	03/11/21
87081	0300, 0306, 0309	Culture, presumptive, pathogenic organisms, screening only	03/11/21
		Culture, presumptive, pathogenic organisms, screening only; with colony	
87084	0300, 0306, 0309	estimation from density chart	03/11/21
87086	0300, 0306, 0309	Culture, bacterial; quantitative colony count, urine	03/11/21
		Culture, bacterial; with isolation and presumptive identification of each	
87088	0300, 0306, 0309	isolate, urine	03/11/21
		Susceptibility studies, antimicrobial agent; agar dilution method, per agent	
87181	0300, 0306, 0309	(eg, antibiotic gradient strip)	03/11/21

		Susceptibility studies, antimicrobial agent; disk method, per plate (12 or	
87184	0300, 0306, 0309	fewer agents)	03/11/21
		Susceptibility studies, antimicrobial agent; microdilution or agar dilution	
		(minimum inhibitory concentration [MIC] or breakpoint), each multi-	
87186	0300, 0306, 0309	antimicrobial, per plate	03/11/21
		Susceptibility studies, antimicrobial agent; microdilution or agar dilution,	
		minimum lethal concentration (MLC), each plate (List separately in addition	
87187	0300, 0306, 0309	to code for primary procedure)	03/11/21
		Susceptibility studies, antimicrobial agent; macrobroth dilution method, each	
87188	0300, 0306, 0309	agent	03/11/21
87230	0300, 0306, 0309	Toxin or antitoxin assay, tissue culture (eg, Clostridium difficile toxin)	03/11/21
		Virus isolation; tissue culture inoculation, observation, and presumptive	
87252	0300, 0306, 0309	identification by cytopathic effect	03/11/21
		Virus isolation; tissue culture, additional studies or definitive identification	
87253	0300, 0306, 0309	(eg, hemabsorption, neutralization, immunofluorescence stain), each isolate	03/11/21
		Infectious agent antigen detection by immunofluorescent technique;	
87280	0300, 0306, 0309	respiratory syncytial virus	03/11/21
		Infectious agent antigen detection by immunoassay technique, (eg, enzyme	
		immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	
0=004	0000 0001 0000	fluorescence immunoassay [FIA], immunochemiluminometric assay	00/11/01
87324	0300, 0306, 0309	[IMCA]) qualitative or semiquantitative; Clostridium difficile toxin(s)	03/11/21
		Infectious agent antigen detection by immunoassay technique, (eg, enzyme	
	0200 0202 0200	immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	
07200	0300, 0302, 0309,	fluorescence immunoassay [FIA], immunochemiluminometric assay	02/11/21
87390	0390	[IMCA]) qualitative or semiquantitative; HIV-1	03/11/21
		Infectious agent antigen detection by immunoassay technique, (eg, enzyme	
	0200 0202 0200	immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	
87391	0300, 0302, 0309, 0390	fluorescence immunoassay [FIA], immunochemiluminometric assay	03/11/21
0/391	0390	[IMCA]) qualitative or semiquantitative; HIV-2	U3/11/21
		Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	
		fluorescence immunoassay [FIA], immunochemiluminometric assay	
87420	0300, 0306, 0309	[IMCA]) qualitative or semiquantitative; respiratory syncytial virus	03/11/21
07420	0300, 0300, 0309	[Invica]) quantative of semiquantitative, respiratory syncytial virus	03/11/41

		Infectious agent detection by nucleic acid (DNA or RNA); central nervous	
		system pathogen (eg, Neisseria meningitidis, Streptococcus pneumoniae,	
		Listeria, Haemophilus influenzae, E. coli, Streptococcus agalactiae,	
		enterovirus, human parechovirus, herpes simplex virus type 1 and 2, human	
		herpesvirus 6, cytomegalovirus, varicella zoster virus, Cryptococcus),	
		includes multiplex reverse transcription, when performed, and multiplex	
87483	0300, 0306	amplified probe technique, multiple types or subtypes, 12-25 targets	03/11/21
		Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia	
87485	0300, 0306, 0309	pneumoniae, direct probe technique	03/11/21
		Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia	
87486	0300, 0306, 0309	pneumoniae, amplified probe technique	03/11/21
		Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia	
87487	0300, 0306, 0309	pneumoniae, quantification	03/11/21
		Infectious agent detection by nucleic acid (DNA or RNA); influenza virus,	
		for multiple types or sub-types, includes multiplex reverse transcription,	
		when performed, and multiplex amplified probe technique, each additional	
		influenza virus type or sub-type beyond 2 (List separately in addition to code	
87503	0300, 0306, 0309	for primary procedure)	03/11/21
0===1	0000 0000 0000	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct	00/44/24
87534	0300, 0306, 0309	probe technique	03/11/21
07.505	0200 0204 0200	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified	00/11/01
87535	0300, 0306, 0309	probe technique, includes reverse transcription when performed	03/11/21
07527	0200 0206 0200	Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct	00/11/01
87537	0300, 0306, 0309	probe technique	03/11/21
97529	0200 0206 0200	Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified	02/11/21
87538	0300, 0306, 0309	probe technique, includes reverse transcription when performed	03/11/21
97590	0200 0206 0200	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma	02/11/21
87580	0300, 0306, 0309	pneumoniae, direct probe technique	03/11/21
87581	0200 0206 0200	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma	02/11/21
0/301	0300, 0306, 0309	pneumoniae, amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma	03/11/21
87582	0300, 0306, 0309	pneumoniae, quantification	03/11/21
01302	0300, 0300, 0309	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus	03/11/21
		(eg, adenovirus, influenza virus, coronavirus, metapneumovirus,	
		parainfluenza virus, respiratory syncytial virus, rhinovirus), includes	
		multiplex reverse transcription, when performed, and multiplex amplified	
87631	0300, 0306	probe technique, multiple types or subtypes, 3-5 targets	03/11/21
07031	1 0 0 0 0 0 0 0 0	proce technique, manaple types of suctypes, 5 5 migets	00/11/21

		Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus		
		(eg, adenovirus, influenza virus, coronavirus, metapneumovirus,		
		parainfluenza virus, respiratory syncytial virus, rhinovirus), includes		
		multiplex reverse transcription, when performed, and multiplex amplified		
87632	0300, 0306	probe technique, multiple types or subtypes, 6-11 targets	03/11/21	
		Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus		
		(eg, adenovirus, influenza virus, coronavirus, metapneumovirus,		
		parainfluenza virus, respiratory syncytial virus, rhinovirus), includes		
		multiplex reverse transcription, when performed, and multiplex amplified		
87633	0300, 0306	probe technique, multiple types or subtypes, 12-25 targets	03/11/21	
		Infectious agent detection by nucleic acid (DNA or RNA); respiratory		
87634	0306	syncytial virus, amplified probe technique	03/11/21	
		Infectious agent detection by nucleic acid (DNA or RNA), multiple		
87801	0300, 0306, 0309	organisms; amplified probe(s) technique	03/11/21	
		Infectious agent antigen detection by immunoassay with direct optical (ie,		
87803	0300, 0306, 0309	visual) observation; Clostridium difficile toxin A	03/11/21	
		Infectious agent antigen detection by immunoassay with direct optical (ie,		
87807	0300, 0306, 0309	visual) observation; respiratory syncytial virus	03/11/21	
		Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid),		
89050	0300, 0309	except blood	03/11/21	
		Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid),		
89051	0300, 0309	except blood; with differential count	03/11/21	
89055	0300, 0309	Leukocyte assessment, fecal, qualitative or semiquantitative	03/11/21	
00070	0.62.6	Respiratory syncytial virus, monoclonal antibody, recombinant, for	00/11/01	
90378	0636	intramuscular use, 50 mg, each	03/11/21	
00000	0321, 0342, 0360,	Percutaneous transluminal coronary angioplasty; single major coronary	00/11/01	
92920	0480, 0481	artery or branch	03/11/21	
	0221 0242 0260	Percutaneous transluminal coronary angioplasty; each additional branch of a		
02021	0321, 0342, 0360,	major coronary artery (List separately in addition to code for primary	02/11/01	
92921	0480, 0481	procedure)	03/11/21	
02024	0321, 0342, 0360,	Percutaneous transluminal coronary atherectomy, with coronary angioplasty	02/11/01	
92924	0480, 0481	when performed; single major coronary artery or branch	03/11/21	
	0221 0242 0260	Percutaneous transcatheter placement of intracoronary stent(s), with		
02028	0321, 0342, 0360,	coronary angioplasty when performed; single major coronary artery or	02/11/21	
92928	0480, 0481	branch Resource and translational accordance who are to great a state of the second accordance with interest accordance with the second accordance with the	03/11/21	
	0221 0242 0260	Percutaneous transluminal coronary atherectomy, with intracoronary stent,		
02022	0321, 0342, 0360,	with coronary angioplasty when performed; single major coronary artery or	02/11/21	
92933	0480, 0481	branch	03/11/21	

		Percutaneous transluminal revascularization of or through coronary artery	
		bypass graft (internal mammary, free arterial, venous), any combination of	
00007	0321, 0342, 0360,	intracoronary stent, atherectomy and angioplasty, including distal protection	00/11/01
92937	0480, 0481	when performed; single vessel	03/11/21
		Percutaneous transluminal revascularization of acute total/subtotal occlusion	
		during acute myocardial infarction, coronary artery or coronary artery bypass	
00044	0250 0400 0404	graft, any combination of intracoronary stent, atherectomy and angioplasty,	00/11/01
92941	0360, 0480, 0481	including aspiration thrombectomy when performed, single vessel	03/11/21
		Percutaneous transluminal revascularization of chronic total occlusion,	
	0221 0242 0260	coronary artery, coronary artery branch, or coronary artery bypass graft, any	
020.42	0321, 0342, 0360,	combination of intracoronary stent, atherectomy and angioplasty; single	02/11/21
92943	0480, 0481	vesse	03/11/21
	0360, 0410, 0419,		
02050	0450, 0480, 0489,		00/11/01
92950	0510, 0519	Cardiopulmonary resuscitation (eg, in cardiac arrest)	03/11/21
02052	0360, 0450, 0480,		00/11/01
92953	0489, 0510, 0519	Temporary transcutaneous pacing	03/11/21
02060	0360, 0450, 0480,		02/11/01
92960	0489, 0510, 0519	Cardioversion, elective, electrical conversion of arrhythmia; external	03/11/21
02061	0360, 0450, 0480,	Cardioversion, elective, electrical conversion of arrhythmia; internal	02/11/01
92961	0489, 0510, 0519	(separate procedure)	03/11/21
92970	0480, 0489	Cardioassist-method of circulatory assist; internal	03/11/21
92971	0480, 0489	Cardioassist-method of circulatory assist; external	03/11/21
02072	0360, 0361, 0480,	Percutaneous transluminal coronary thrombectomy mechanical (List	02/11/01
92973	0481	separately in addition to code for primary procedure)	03/11/21
02075	0260 0400 0401	Thrombolysis, coronary; by intracoronary infusion, including selective	00/11/01
92975	0360, 0480, 0481	coronary angiography	03/11/21
02077	0360, 0361, 0480,		00/11/01
92977	0481	Thrombolysis, coronary; by intravenous infusion	03/11/21
		Endoluminal imaging of coronary vessel or graft using intravascular	
		ultrasound (IVUS) or optical coherence tomography (OCT) during	
	0260 0261 0402	diagnostic evaluation and/or therapeutic intervention including imaging	
02070	0360, 0361, 0402,	supervision, interpretation and report; initial vessel (List separately in	00/11/01
92978	0480, 0481	addition to code for primary procedure)	03/11/21

		Endoluminal imaging of coronary vessel or graft using intravascular		
		ultrasound (IVUS) or optical coherence tomography (OCT) during		
		diagnostic evaluation and/or therapeutic intervention including imaging		
	0360, 0361, 0402,	supervision, interpretation and report; each additional vessel (List separately		
92979	0480, 0481	in addition to code for primary procedure)	03/11/21	
		Electrocardiogram, routine ECG with at least 12 leads; interpretation and		
93010	0521, 0985	report only	03/11/21	
		Cardiovascular stress test using maximal or submaximal treadmill or bicycle		
		exercise, continuous electrocardiographic monitoring, and/or		
93015	0482, 0985	pharmacological stress; with supervision, interpretation and report	03/11/21	
		Cardiovascular stress test using maximal or submaximal treadmill or bicycle		
		exercise, continuous electrocardiographic monitoring, and/or		
93016	0482, 0985	pharmacological stress; supervision only, without interpretation and report	03/11/21	
		Cardiovascular stress test using maximal or submaximal treadmill or bicycle		
		exercise, continuous electrocardiographic monitoring, and/or		
93017	0482, 0730	pharmacological stress; tracing only, without interpretation and report	03/11/21	
		Cardiovascular stress test using maximal or submaximal treadmill or bicycle		
		exercise, continuous electrocardiographic monitoring, and/or		
93018	0482, 0521, 0985	pharmacological stress; interpretation and report only	03/11/21	
93025	0480, 0489, 0730	Microvolt T-wave alternans for assessment of ventricular arrhythmias	03/11/21	
93040	0730	Rhythm ECG, 1-3 leads; with interpretation and report	03/11/21	
93041	0521, 0730, 0985	Rhythm ECG, 1-3 leads; tracing only without interpretation and report	03/11/21	
93042	0521, 0730, 0985	Rhythm ECG, 1-3 leads; interpretation and report only	03/11/21	
93278	0730, 0731	Signal-averaged electrocardiography (SAECG), with or without ECG	03/11/21	
		Echocardiography, transthoracic, real-time with image documentation (2D),		
		includes M-mode recording, when performed, complete, with spectral		
93306	0483	Doppler echocardiography, and with color flow Doppler echocardiography	03/11/21	
		Echocardiography, transthoracic, real-time with image documentation (2D),		
		includes M-mode recording, when performed, complete, without spectral or		
93307	0483	color Doppler echocardiography	03/11/21	
		Echocardiography, transthoracic, real-time with image documentation (2D),		
93308	0483	includes M-mode recording, when performed, follow-up or limited study	03/11/21	
		Echocardiography, transesophageal, real-time with image documentation		
		(2D) (with or without M-mode recording); including probe placement, image		
93312	0483	acquisition, interpretation and report	03/11/21	
		Echocardiography, transesophageal, real-time with image documentation		
		(2D) (with or without M-mode recording); placement of transesophageal		
93313	0483	probe only	03/11/21	

		Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); image acquisition, interpretation		
93314	0483	and report only	03/11/21	
		Echocardiography, transesophageal (TEE) for monitoring purposes,		
		including probe placement, real time 2-dimensional image acquisition and		
		interpretation leading to ongoing (continuous) assessment of (dynamically		
		changing) cardiac pumping function and to therapeutic measures on an		
93318	0483	immediate time basis	03/11/21	
		Doppler echocardiography, pulsed wave and/or continuous wave with		
		spectral display (List separately in addition to codes for echocardiographic		
93320	0483	imaging); complete	03/11/21	
		Doppler echocardiography, pulsed wave and/or continuous wave with		
		spectral display (List separately in addition to codes for echocardiographic		
		imaging); follow-up or limited study (List separately in addition to codes for		
93321	0483	echocardiographic imaging)	03/11/21	
		Doppler echocardiography color flow velocity mapping (List separately in		
93325	0483	addition to codes for echocardiography)	03/11/21	
		Echocardiography, transthoracic, real-time with image documentation (2D),		
		includes M-mode recording, when performed, during rest and cardiovascular		
		stress test using treadmill, bicycle exercise and/or pharmacologically		
93350	0483	induced stress, with interpretation and report	03/11/21	
		Echocardiography, transthoracic, real-time with image documentation (2D),		
		includes M-mode recording, when performed, during rest and cardiovascular		
		stress test using treadmill, bicycle exercise and/or pharmacologically		
		induced stress, with interpretation and report; including performance of		
		continuous electrocardiographic monitoring, with supervision by a physician		
93351	0483	or other qualified health care professional	03/11/21	
		Use of echocardiographic contrast agent during stress echocardiography		
93352	0483	(List separately in addition to code for primary procedure)	03/11/21	
		Right heart catheterization including measurement(s) of oxygen saturation		
93451	0481	and cardiac output, when performed	03/11/21	
		Left heart catheterization including intraprocedural injection(s) for left		
93452	0481	ventriculography, imaging supervision and interpretation, when performed	03/11/21	
		Combined right and left heart catheterization including intraprocedural		
		injection(s) for left ventriculography, imaging supervision and interpretation,		
93453	0481	when performed	03/11/21	

		Catheter placement in coronary artery(s) for coronary angiography,		
		including intraprocedural injection(s) for coronary angiography, imaging		
93454	0481	supervision and interpretation	03/11/21	
		Catheter placement in coronary artery(s) for coronary angiography,		
		including intraprocedural injection(s) for coronary angiography, imaging		
		supervision and interpretation; with catheter placement(s) in bypass graft(s)		
		(internal mammary, free arterial, venous grafts) including intraprocedural		
93455	0481	injection(s) for bypass graft angiography	03/11/21	
		Catheter placement in coronary artery(s) for coronary angiography,		
		including intraprocedural injection(s) for coronary angiography, imaging		
93456	0481	supervision and interpretation; with right heart catheterization	03/11/21	
		Catheter placement in coronary artery(s) for coronary angiography,		
		including intraprocedural injection(s) for coronary angiography, imaging		
		supervision and interpretation; with catheter placement(s) in bypass graft(s)		
		(internal mammary, free arterial, venous grafts) including intraprocedural		
93457	0481	injection(s) for bypass graft angiography and right heart catheterization	03/11/21	
		Catheter placement in coronary artery(s) for coronary angiography,		
		including intraprocedural injection(s) for coronary angiography, imaging		
		supervision and interpretation; with left heart catheterization including		
93458	0481	intraprocedural injection(s) for left ventriculography, when performed	03/11/21	
		Catheter placement in coronary artery(s) for coronary angiography,		
		including intraprocedural injection(s) for coronary angiography, imaging		
		supervision and interpretation; with left heart catheterization including		
		intraprocedural injection(s) for left ventriculography, when performed,		
		catheter placement(s) in bypass graft(s) (internal mammary, free arterial,		
93459	0481	venous grafts) with bypass graft angiography	03/11/21	
		Catheter placement in coronary artery(s) for coronary angiography,		
		including intraprocedural injection(s) for coronary angiography, imaging		
		supervision and interpretation; with right and left heart catheterization		
		including intraprocedural injection(s) for left ventriculography, when		
93460	0481	performed	03/11/21	
		Catheter placement in coronary artery(s) for coronary angiography,		
		including intraprocedural injection(s) for coronary angiography, imaging		
		supervision and interpretation; with right and left heart catheterization		
		including intraprocedural injection(s) for left ventriculography, when		
		performed, catheter placement(s) in bypass graft(s) (internal mammary, free		
93461	0481	arterial, venous grafts) with bypass graft angiography	03/11/21	

		Left heart catheterization by transseptal puncture through intact septum or by		
		transapical puncture (List separately in addition to code for primary		
93462	0481	procedure)	03/11/21	
		Pharmacologic agent administration (eg, inhaled nitric oxide, intravenous		
		infusion of nitroprusside, dobutamine, milrinone, or other agent) including		
		assessing hemodynamic measurements before, during, after and repeat		
		pharmacologic agent administration, when performed (List separately in		
93463	0481	addition to code for primary procedure)	03/11/21	
		Insertion and placement of flow directed catheter (eg, Swan-Ganz) for		
93503	0481	monitoring purposes	03/11/21	
93505	0481	Endomyocardial biopsy	03/11/21	
		Indicator dilution studies such as dye or thermodilution, including arterial		
		and/or venous catheterization; with cardiac output measurement (separate		
93561	0481	procedure)	03/11/21	
		Indicator dilution studies such as dye or thermodilution, including arterial		
93562	0481	and/or venous catheterization; subsequent measurement of cardiac output	03/11/21	
		Injection procedure during cardiac catheterization including imaging		
		supervision, interpretation, and report; for selective left ventricular or left		
93565	0481	atrial angiography (List separately in addition to code for primary procedure)	03/11/21	
		Injection procedure during cardiac catheterization including imaging		
		supervision, interpretation, and report; for selective right ventricular or right		
93566	0481	atrial angiography (List separately in addition to code for primary procedure)	03/11/21	
		Injection procedure during cardiac catheterization including imaging		
		supervision, interpretation, and report; for supravalvular aortography (List		
93567	0481	separately in addition to code for primary procedure)	03/11/21	
		Injection procedure during cardiac catheterization including imaging		
		supervision, interpretation, and report; for pulmonary angiography (List		
93568	0481	separately in addition to code for primary procedure)	03/11/21	
		Intravascular Doppler velocity and/or pressure derived coronary flow reserve		
		measurement (coronary vessel or graft) during coronary angiography		
		including pharmacologically induced stress; initial vessel (List separately in		
93571	0480, 0481	addition to code for primary procedure)	03/11/21	
		Intravascular Doppler velocity and/or pressure derived coronary flow reserve		
		measurement (coronary vessel or graft) during coronary angiography		
		including pharmacologically induced stress; each additional vessel (List		
93572	0480, 0481	separately in addition to code for primary procedure)	03/11/21	

		Intraventricular and/or intra-atrial mapping of tachycardia site(s) with		
		catheter manipulation to record from multiple sites to identify origin of		
93609	0480, 0481	tachycardia (List separately in addition to code for primary procedure)	03/11/21	
93610	0480, 0481	Intra-atrial pacing	03/11/21	
93612	0480, 0481	Intraventricular pacing	03/11/21	
		Intracardiac electrophysiologic 3-dimensional mapping (List separately in		
93613	0480, 0481	addition to code for primary procedure)	03/11/21	
93618	0480, 0481	Induction of arrhythmia by electrical pacing	03/11/21	
		Comprehensive electrophysiologic evaluation with right atrial pacing and		
		recording, right ventricular pacing and recording, His bundle recording,		
		including insertion and repositioning of multiple electrode catheters, without		
93619	0480	induction or attempted induction of arrhythmia	03/11/21	
		Comprehensive electrophysiologic evaluation including insertion and		
		repositioning of multiple electrode catheters with induction or attempted		
		induction of arrhythmia; with right atrial pacing and recording, right		
93620	0480	ventricular pacing and recording, His bundle recording	03/11/21	
		Comprehensive electrophysiologic evaluation including insertion and		
		repositioning of multiple electrode catheters with induction or attempted		
		induction of arrhythmia; with left atrial pacing and recording from coronary		
		sinus or left atrium (List separately in addition to code for primary		
93621	0480, 0481	procedure)	03/11/21	
		Comprehensive electrophysiologic evaluation including insertion and		
		repositioning of multiple electrode catheters with induction or attempted		
		induction of arrhythmia; with left ventricular pacing and recording (List		
93622	0480, 0481	separately in addition to code for primary procedure)	03/11/21	
		Programmed stimulation and pacing after intravenous drug infusion (List		
93623	0480, 0481	separately in addition to code for primary procedure)	03/11/21	
		Electrophysiologic follow-up study with pacing and recording to test		
		effectiveness of therapy, including induction or attempted induction of		
93624	0480	arrhythmia	03/11/21	
		Intra-operative epicardial and endocardial pacing and mapping to localize		
93631	0480, 0481	the site of tachycardia or zone of slow conduction for surgical correction	03/11/21	
		Intracardiac catheter ablation of atrioventricular node function,		
00.00	0.400.0121	atrioventricular conduction for creation of complete heart block, with or	00/44/2	
93650	0480, 0481	without temporary pacemaker placement	03/11/21	

			I	
		Comprehensive electrophysiologic evaluation including insertion and		
		repositioning of multiple electrode catheters with induction or attempted		
		induction of an arrhythmia with right atrial pacing and recording, right		
		ventricular pacing and recording (when necessary), and His bundle recording		
		(when necessary) with intracardiac catheter ablation of arrhythmogenic		
		focus; with treatment of supraventricular tachycardia by ablation of fast or		
		slow atrioventricular pathway, accessory atrioventricular connection, cavo-		
93653	0480, 0481	tricuspid isthmus or other single atrial focus or source of atrial re-entry	03/11/21	
		Comprehensive electrophysiologic evaluation including insertion and		
		repositioning of multiple electrode catheters with induction or attempted		
		induction of an arrhythmia with right atrial pacing and recording, right		
		ventricular pacing and recording (when necessary), and His bundle recording		
		(when necessary) with intracardiac catheter ablation of arrhythmogenic		
		focus; with treatment of ventricular tachycardia or focus of ventricular		
		ectopy including intracardiac electrophysiologic 3D mapping, when		
93654	0480, 0481	performed, and left ventricular pacing and recording, when performed	03/11/21	
		Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is		
		distinct from the primary ablated mechanism, including repeat diagnostic		
		maneuvers, to treat a spontaneous or induced arrhythmia (List separately in		
93655	0480, 0481	addition to code for primary procedure)	03/11/21	
		Comprehensive electrophysiologic evaluation including transseptal		
		catheterizations, insertion and repositioning of multiple electrode catheters		
		with induction or attempted induction of an arrhythmia including left or right		
		atrial pacing/recording when necessary, right ventricular pacing/recording		
		when necessary, and His bundle recording when necessary with intracardiac		
93656	0480, 0481	catheter ablation of atrial fibrillation by pulmonary vein isolation	03/11/21	
75050	0 100, 0 101	Additional linear or focal intracardiac catheter ablation of the left or right	03/11/21	
		atrium for treatment of atrial fibrillation remaining after completion of		
		pulmonary vein isolation (List separately in addition to code for primary		
93657	0480, 0481	procedure)	03/11/21	
73037	0460, 0461	Intracardiac echocardiography during therapeutic/diagnostic intervention,	03/11/21	
02662	0490 0492	including imaging supervision and interpretation (List separately in addition	02/11/21	
93662	0480, 0482	to code for primary procedure)	03/11/21	
02707	0042	Physician or other qualified health care professional services for outpatient	02/11/21	
93797	0943	cardiac rehabilitation; without continuous ECG monitoring (per session)	03/11/21	
02700	00.42	Physician or other qualified health care professional services for outpatient	02/11/21	
93798	0943	cardiac rehabilitation; with continuous ECG monitoring (per session)	03/11/21	
02070	0021 0020	Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts;	02/11/21	
93978	0921, 0929	complete study	03/11/21	

		Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts;	
93979	0921, 0929	unilateral or limited study	03/11/21
		Ventilation assist and management, initiation of pressure or volume preset	
		ventilators for assisted or controlled breathing; hospital	
94002	0410, 0419	inpatient/observation, initial day	03/11/21
		Ventilation assist and management, initiation of pressure or volume preset	
		ventilators for assisted or controlled breathing; hospital	
94003	0410, 0419	inpatient/observation, each subsequent day	03/11/21
		Spirometry, including graphic record, total and timed vital capacity,	
		expiratory flow rate measurement(s), with or without maximal voluntary	
94010	0460, 0469	ventilation	03/11/21
		Measurement of spirometric forced expiratory flows in an infant or child	
94011	0460, 0469	through 2 years of age	03/11/21
		Measurement of spirometric forced expiratory flows, before and after	
94012	0460, 0469	bronchodilator, in an infant or child through 2 years of age	03/11/21
		Measurement of lung volumes (ie, functional residual capacity [FRC], forced	
		vital capacity [FVC], and expiratory reserve volume [ERV]) in an infant or	
94013	0460, 0469	child through 2 years of age	03/11/21
		Bronchodilation responsiveness, spirometry as in 94010, pre- and post-	
94060	0460, 0469	bronchodilator administration	03/11/21
		Bronchospasm provocation evaluation, multiple spirometric determinations	
94070	0460, 0469	as in 94010, with administered agents (eg, antigen[s], cold air, methacholine)	03/11/21
94150	0460, 0469	Vital capacity, total (separate procedure)	03/11/21
94200	0460, 0469	Maximum breathing capacity, maximal voluntary ventilation	03/11/21
94375	0460, 0469	Respiratory flow volume loop	03/11/21
94450	0460, 0469	Breathing response to hypoxia (hypoxia response curve)	03/11/21
		Intrapulmonary surfactant administration by a physician or other qualified	
94610	0460, 0469	health care professional through endotracheal tube	03/11/21
		Cardiopulmonary exercise testing, including measurements of minute	
94621	0460, 0469, 0482	ventilation, CO2 production, O2 uptake, and electrocardiographic recordings	03/11/21
		Pressurized or nonpressurized inhalation treatment for acute airway	
		obstruction for therapeutic purposes and/or for diagnostic purposes such as	
		sputum induction with an aerosol generator, nebulizer, metered dose inhaler	
94640	0410, 0412, 0419	or intermittent positive pressure breathing (IPPB) device	03/11/21
		Continuous inhalation treatment with aerosol medication for acute airway	
94644	0410, 0412, 0419	obstruction; first hour	03/11/21

		Continuous inhalation treatment with aerosol medication for acute airway		
		obstruction; each additional hour (List separately in addition to code for		
94645	0410, 0412, 0419	primary procedure)	03/11/21	
		Continuous positive airway pressure ventilation (CPAP), initiation and		
94660	0410, 0412, 0419	management	03/11/21	
94662	0410, 0412, 0419	Continuous negative pressure ventilation (CNP), initiation and management	03/11/21	
		Demonstration and/or evaluation of patient utilization of an aerosol		
94664	0410, 0412, 0419	generator, nebulizer, metered dose inhaler or IPPB device	03/11/21	
		Manipulation chest wall, such as cupping, percussing, and vibration to		
94667	0410, 0412, 0419	facilitate lung function; initial demonstration and/or evaluation	03/11/21	
		Manipulation chest wall, such as cupping, percussing, and vibration to		
94668	0410, 0412, 0419	facilitate lung function; subsequent	03/11/21	
94669	0410, 0412, 0419	Mechanical chest wall oscillation to facilitate lung function, per session	03/11/21	
		Plethysmography for determination of lung volumes and, when performed,		
94726	0460, 0469	airway resistance	03/11/21	
		Gas dilution or washout for determination of lung volumes and, when		
94727	0460, 0469	performed, distribution of ventilation and closing volumes	03/11/21	
94728	0460, 0469	Airway resistance by oscillometry	03/11/21	
		Diffusing capacity (eg, carbon monoxide, membrane) (List separately in		
94729	0460, 0469	addition to code for primary procedure)	03/11/21	
		Noninvasive ear or pulse oximetry for oxygen saturation; single		
94760	0460, 0469	determination	03/11/21	
		Noninvasive ear or pulse oximetry for oxygen saturation; multiple		
94761	0460, 0469	determinations (eg, during exercise)	03/11/21	
		Noninvasive ear or pulse oximetry for oxygen saturation; by continuous		
94762	0460, 0469	overnight monitoring (separate procedure)	03/11/21	
		Testing of autonomic nervous system function; combined parasympathetic		
		and sympathetic adrenergic function testing with at least 5 minutes of		
95924	0922, 0929	passive tilt	03/11/21	
		Simultaneous, independent, quantitative measures of both parasympathetic		
		function and sympathetic function, based on time-frequency analysis of heart		
		rate variability concurrent with time-frequency analysis of continuous		
		respiratory activity, with mean heart rate and blood pressure measures,		
		during rest, paced (deep) breathing, Valsalva maneuvers, and head-up		
95943	0922, 0929	postural change	03/11/21	

0260, 0361, 0450,			
0510, 0511, 0514,			
0515, 0516, 0517,			
	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify		
0940,		03/11/21	
0260, 0361, 0450,			
	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify		
0940,		03/11/21	
0260, 0361, 0450,			
1 1			
1 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify		
		03/11/21	
		32,72,22	
	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify		
	, <u> </u>	03/11/21	
1 1	Subcutaneous infusion for therapy or prophylaxis (specify substance or		
1 1			
0940,		03/11/21	
0260, 0361, 0450,			
0510, 0511, 0514,			
0515, 0516, 0517,			
0519, 0520, 0523,	Subcutaneous infusion for therapy or prophylaxis (specify substance or		
0940,	procedure)	03/11/21	
	0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920,	0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0920, 0940, 0260, 0361, 0450, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0920, 0940, 0260, 0361, 0450, 0361,	0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 30526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0520, 0523, 0526, 0529, 0920, 0940, 0510, 0511, 0514, 0515, 0516, 0517, 0519, 0520, 0523, 0526, 0529, 0920, 0520, 0523, 0526, 0529, 0920, 0520, 0523, 0526, 0529, 0920, 0520, 0523, 0526, 0529, 0920, 0520, 0523, 0526, 0529, 0920, 0520, 0523, 0526, 0529, 0920, 0520, 0523, 0526, 0529, 0920, 0520, 0523, 0526, 0529, 0920, 0520, 0523, 0526, 0529, 0920, 052

l l
/11/21
/11/21
/11/21
/11/21
/11/21
/11/21
/11/21

		Observation or inpatient hospital care, for the evaluation and management of		
		a patient including admission and discharge on the same date, which requires		
		these 3 key components: A detailed or comprehensive history; A detailed or		
		comprehensive examination; and Medical decision making that is		
		straightforward or of low complexity.		
		Counseling and/or coordination of care with other physicians, other qualified		
		health care professionals, or agencies are provided consistent with the nature		
		of the problem(s) and the patient's and/or family's needs. Usually the		
		presenting problem(s) requiring admission are of low severity. Typically, 40		
99234	0657, 0762, 0987	minutes are spent at the bedside and on the patient's hospital floor or unit.	03/11/21	
		Observation or inpatient hospital care, for the evaluation and management of		
		a patient including admission and discharge on the same date, which requires		
		these 3 key components: A comprehensive history; A comprehensive		
		examination; and Medical decision making of moderate complexity.		
		Counseling and/or coordination of care with other physicians, other qualified		
		health care professionals, or agencies are provided consistent with the nature		
		of the problem(s) and the patient's and/or family's needs. Usually the		
		presenting problem(s) requiring admission are of moderate severity.		
		Typically, 50 minutes are spent at the bedside and on the patient's hospital		
99235	0657, 0762, 0987	floor or unit.	03/11/21	
		Observation or inpatient hospital care, for the evaluation and management of		
		a patient including admission and discharge on the same date, which requires		
		these 3 key components: A comprehensive history; A comprehensive		
		examination; and Medical decision making of high complexity. Counseling		
		and/or coordination of care with other physicians, other qualified health care		
		professionals, or agencies are provided consistent with the nature of the		
		problem(s) and the patient's and/or family's needs. Usually the presenting		
0000	0.455 0545 0005	problem(s) requiring admission are of high severity. Typically, 55 minutes	00/44/04	
99236	0657, 0762, 0987	are spent at the bedside and on the patient's hospital floor or unit.	03/11/21	
99238	0657, 0987	Hospital discharge day management; 30 minutes or less	03/11/21	
99239	0657, 0987	Hospital discharge day management; more than 30 minutes	03/11/21	
	0450, 0452, 0456,			
	0459, 0510, 0512,	Prolonged service(s) in the outpatient setting requiring direct patient contact		
	0513, 0514, 0515,	beyond the time of the usual service; first hour (List separately in addition to		
	0516, 0517, 0519,	code for outpatient Evaluation and Management or psychotherapy service,		
00254	0520, 0526, 0529,	except with office or other outpatient services [99202, 99203, 99204, 99205,	02/11/21	
99354	0657, 0761, 0900	99212, 99213, 99214, 99215])	03/11/21	

	0450, 0452, 0456,		
	0459, 0510, 0512,		
	0513, 0514, 0515,		
	0516, 0517, 0519,	Prolonged service(s) in the outpatient setting requiring direct patient contact	
	0520, 0526, 0529,	beyond the time of the usual service; each additional 30 minutes (List	
99355	0657, 0761, 0900	separately in addition to code for prolonged service)	03/11/21
		Prolonged service in the inpatient or observation setting, requiring unit/floor	
		time beyond the usual service; first hour (List separately in addition to code	
99356	0987	for inpatient or observation Evaluation and Management service)	03/11/21
		Prolonged service in the inpatient or observation setting, requiring unit/floor	
		time beyond the usual service; each additional 30 minutes (List separately in	
99357	0987	addition to code for prolonged service)	03/11/21
	0450, 0452, 0456,		
	0459, 0510, 0520,		
	0657, 0960, 0969,		
	0981, 0982, 0983,	Prolonged evaluation and management service before and/or after direct	
99358	0987, 0988	patient care; first hour	03/11/21
	0450, 0452, 0456,		
	0459, 0510, 0512,		
	0513, 0514, 0515,		
	0516, 0517, 0519,	Prolonged evaluation and management service before and/or after direct	
	0520, 0529, 0657,	patient care; each additional 30 minutes (List separately in addition to code	
99359	0960, 0969, 0981	for prolonged service)	03/11/21
		Interprofessional telephone/Internet/electronic health record assessment and	
		management service provided by a consultative physician, including a verbal	
		and written report to the patient's treating/requesting physician or other	
		qualified health care professional; 5-10 minutes of medical consultative	
99446	0988	discussion and review	03/11/21
		Interprofessional telephone/Internet/electronic health record assessment and	
		management service provided by a consultative physician, including a verbal	
		and written report to the patient's treating/requesting physician or other	
		qualified health care professional; 11-20 minutes of medical consultative	
99447	0988	discussion and review	03/11/21
		Interprofessional telephone/Internet/electronic health record assessment and	
		management service provided by a consultative physician, including a verbal	
		and written report to the patient's treating/requesting physician or other	
		qualified health care professional; 21-30 minutes of medical consultative	
99448	0988	discussion and review	03/11/21

		Interprofessional telephone/Internet/electronic health record assessment and	
		management service provided by a consultative physician, including a verbal	
		and written report to the patient's treating/requesting physician or other	
		qualified health care professional; 31 minutes or more of medical	
99449	0988	consultative discussion and review	03/11/21
		Interprofessional telephone/Internet/electronic health record assessment and	
		management service provided by a consultative physician, including a	
		written report to the patient's treating/requesting physician or other qualified	
99451	0988	health care professional, 5 minutes or more of medical consultative time	03/11/21
		Interprofessional telephone/Internet/electronic health record referral	
		service(s) provided by a treating/requesting physician or other qualified	
99452	0988	health care professional, 30 minutes	03/11/21
	0456, 0510, 0516,	Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure,	
	0517, 0519, 0520,	pulse oximetry, respiratory flow rate), initial; device(s) supply with daily	
99454	0920	recording(s) or programmed alert(s) transmission, each 30 days	03/11/21
		Delivery/birthing room resuscitation, provision of positive pressure	
		ventilation and/or chest compressions in the presence of acute inadequate	
99465	0722, 0724, 0987	ventilation and/or cardiac output	03/11/21
		Initial inpatient neonatal critical care, per day, for the evaluation and	
99468	0987	management of a critically ill neonate, 28 days of age or younger	03/11/21
		Subsequent inpatient neonatal critical care, per day, for the evaluation and	
99469	0987	management of a critically ill neonate, 28 days of age or younger	03/11/21
		Initial inpatient pediatric critical care, per day, for the evaluation and	
		management of a critically ill infant or young child, 29 days through 24	
99471	0987	months of age	03/11/21
		Subsequent inpatient pediatric critical care, per day, for the evaluation and	
00.4=0		management of a critically ill infant or young child, 29 days through 24	00/11/01
99472	0987	months of age	03/11/21
00.45		Initial inpatient pediatric critical care, per day, for the evaluation and	00/11/01
99475	0987	management of a critically ill infant or young child, 2 through 5 years of age	03/11/21
00.45	0005	Subsequent inpatient pediatric critical care, per day, for the evaluation and	00/11/01
99476	0987	management of a critically ill infant or young child, 2 through 5 years of age	03/11/21
		Subsequent intensive care, per day, for the evaluation and management of	
00.470	0007	the recovering low birth weight infant (present body weight of 1500-2500	02/11/21
99479	0987	grams)	03/11/21
00.400	0007	Subsequent intensive care, per day, for the evaluation and management of	02/11/21
99480	0987	the recovering infant (present body weight of 2501-5000 grams)	03/11/21

		Supervision by a control physician of interfacility transport care of the	
		critically ill or critically injured pediatric patient, 24 months of age or	
		younger, includes two-way communication with transport team before	
99485	0450, 0981	transport, at the referring facility and during the transport, including data interpretation and report; first 30 minutes	03/11/21
99483	0430, 0981	Supervision by a control physician of interfacility transport care of the	05/11/21
		critically ill or critically injured pediatric patient, 24 months of age or	
		younger, includes two-way communication with transport team before	
		transport, at the referring facility and during the transport, including data	
		interpretation and report; each additional 30 minutes (List separately in	
99486	0450, 0981	addition to code for primary procedure)	03/11/21
<i>>></i> 100	0.20, 0.01	Transitional Care Management Services with the following required	03/11/21
		elements:	
		Communication (direct contact, telephone, electronic) with the patient and/or	
		caregiver within 2 business days of discharge	
	0510, 0512, 0513,	Medical decision making of at least moderate complexity during the service	
	0514, 0515, 0517,	period	
99495	0519, 0520, 0521	Face-to-face visit, within 14 calendar days of discharge	03/11/21
		Transitional Care Management Services with the following required	
		elements:	
	0.510 0.510 0.510	Communication (direct contact, telephone, electronic) with the patient and/or	
	0510, 0512, 0513,	caregiver within 2 business days of discharge	
00406	0514, 0515, 0517,	Medical decision making of high complexity during the service period	02/11/21
99496	0519, 0520, 0521	Face-to-face visit, within 7 calendar days of discharge	03/11/21
	0510, 0512, 0513,	Advance care planning including the explanation and discussion of advance	
	0514, 0515, 0517, 0519, 0520, 0521,	directives such as standard forms (with completion of such forms, when performed), by the physician or other qualified health care professional; first	
99497	0770, 0969	30 minutes, face-to-face with the patient, family member(s), and/or surrogate	03/11/21
77 4 71	0550, 0551, 0552,	50 minutes, race-to-race with the patient, raining member(s), and/or surrogate	03/11/21
	0559, 0570, 0571,		
	0572, 0579, 0580,		
	0581, 0582, 0583,		
99601	0589, 0590	Home infusion/specialty drug administration, per visit (up to 2 hours)	03/11/21
	0550, 0551, 0552,	, , , , , , , , , , , , , , , , , , , ,	
	0559, 0570, 0571,	Home infusion/specialty drug administration, per visit (up to 2 hours); each	
99602	0572, 0579	additional hour (List separately in addition to code for primary procedure)	03/11/21

	0360, 0361, 0450,	Insertion of chest wall respiratory sensor electrode or electrode array,	
	0510, 0515, 0516,	including connection to pulse generator (List separately in addition to code	
0466T	0517, 0519, 0761	for primary procedure)	03/11/21
A4218	0272	Sterile saline or water, metered dose dispenser, 10 ml	03/11/21
A4483	0272	Moisture exchanger, disposable, for use with invasive mechanical ventilation	03/11/21
A4605	0271, 0294	Tracheal suction catheter, closed system, each	03/11/21
A4615	0271, 0294	Cannula, nasal	03/11/21
A4616	0271, 0294	Tubing (oxygen), per foot	03/11/21
A4617	0271, 0294	Mouth piece	03/11/21
A4618	0271, 0294	Breathing circuits	03/11/21
A4619	0271, 0294	Face tent	03/11/21
A4620	0271, 0294	Variable concentration mask	03/11/21
A4624	0271, 0294	Tracheal suction catheter, any type other than closed system, each	03/11/21
		Spacer, bag or reservoir, with or without mask, for use with metered dose	
A4627	0271	inhaler	03/11/21
A4628	0271, 0294	Oropharyngeal suction catheter, each	03/11/21
	0272, 0822, 0832,		
A4657	0842, 0852	Syringe, with or without needle, each	03/11/21
	0822, 0832, 0842,		
A4928	0852	Surgical mask, per 20	03/11/21
	0272, 0822, 0832,		
A4931	0842, 0852	Oral thermometer, reusable, any type, each	03/11/21
A4932	0294	Rectal thermometer, reusable, any type, each	03/11/21
		Housing and integrated adhesive, for use in a tracheostoma heat and	
A7508	0274	moisture exchange system and/or with a tracheostoma valve, each	03/11/21
		Filter holder and integrated filter housing, and adhesive, for use as a	
A7509	0274	tracheostoma heat and moisture exchange system, each	03/11/21
		Catheter, infusion, inserted peripherally, centrally or midline (other than	
C1751	0278	hemodialysis)	03/11/21
		Stationary compressed gaseous oxygen system, rental; includes container,	
	0271, 0601, 0602,	contents, regulator, flowmeter, humidifier, nebulizer, cannula or mask, and	00/44/04
E0424	0603	tubing	03/11/21
F0.424	0271, 0601, 0602,	Portable gaseous oxygen system, rental; includes portable container,	00/11/01
E0431	0603	regulator, flowmeter, humidifier, cannula or mask, and tubing	03/11/21
	0071 0001 000	Portable liquid oxygen system, rental; includes portable container, supply	
E0424	0271, 0601, 0602,	reservoir, humidifier, flowmeter, refill adaptor, contents gauge, cannula or	02/11/21
E0434	0603	mask, and tubing	03/11/21

	0271, 0601, 0602,	Stationary liquid oxygen system, rental; includes container, contents,		
E0439	0603	regulator, flowmeter, humidifier, nebulizer, cannula or mask, & tubing	03/11/21	
	0271, 0601, 0602,			
E0441	0603	Stationary oxygen contents, gaseous, 1 month's supply = 1 unit	03/11/21	
70116	0271, 0601, 0602,		00/11/01	
E0442	0603	Stationary oxygen contents, liquid, 1 month's supply = 1 unit	03/11/21	
F0.440	0271, 0601, 0602,		00/11/01	
E0443	0603	Portable oxygen contents, gaseous, 1 month's supply = 1 unit	03/11/21	
E0444	0271, 0601, 0602,		02/11/01	
E0444	0603	Portable oxygen contents, liquid, 1 month's supply = 1 unit	03/11/21	
E0445	0271, 0601, 0602,		02/11/21	
E0445	0603	Oximeter device for measuring blood oxygen levels noninvasively	03/11/21	
E0455	0271, 0294	Oxygen tent, excluding croup or pediatric tents	03/11/21	
E0465	0271 0204	Home ventilator, any type, used with invasive interface, (e.g., tracheostomy tube)	03/11/21	
E0403	0271, 0294	Home ventilator, any type, used with non-invasive interface, (e.g., mask,	03/11/21	
E0466	0271, 0294	chest shell)	03/11/21	
E0400	0271, 0294	Home ventilator, multi-function respiratory device, also performs any or all	03/11/21	
		of the additional functions of oxygen concentration, drug nebulization,		
		aspiration, and cough stimulation, includes all accessories, components and		
E0467	0292	supplies for all functions	03/11/21	
LOTO	02)2	Respiratory assist device, bi-level pressure capability, without backup rate	03/11/21	
	0271, 0291, 0292,	feature, used with noninvasive interface, e.g., nasal or facial mask		
E0470	0293	(intermittent assist device with continuous positive airway pressure device)	03/11/21	
	10270	Respiratory assist device, bi-level pressure capability, with back-up rate	30,721,22	
	0271, 0291, 0292,	feature, used with noninvasive interface, e.g., nasal or facial mask		
E0471	0293	(intermittent assist device with continuous positive airway pressure device)	03/11/21	
		Respiratory assist device, bi-level pressure capability, with backup rate		
	0271, 0291, 0292,	feature, used with invasive interface, e.g., tracheostomy tube (intermittent		
E0472	0293	assist device with continuous positive airway pressure device)	03/11/21	
	0271, 0291, 0292,	IPPB machine, all types, with built-in nebulization; manual or automatic		
E0500	0293	valves; internal or external power source	03/11/21	
	0271, 0291, 0292,	Humidifier, durable for extensive supplemental humidification during IPPB		
E0550	0293	treatments or oxygen delivery	03/11/21	
	0271, 0291, 0292,	Humidifier, durable, glass or autoclavable plastic bottle type, for use with		
E0555	0293	regulator or flowmeter	03/11/21	
	0271, 0291, 0292,	Humidifier, durable for supplemental humidification during IPPB treatment		
E0560	0293	or oxygen delivery	03/11/21	

	0271, 0291, 0292,	Compressor, air power source for equipment which is not self- contained or		
E0565	0293	cylinder driven	03/11/21	
	0271, 0291, 0292,			
E0570	0293	Nebulizer, with compressor	03/11/21	
	0271, 0291, 0292,			
E0572	0293	Aerosol compressor, adjustable pressure, light duty for intermittent use	03/11/21	
	0271, 0291, 0292,			
E0574	0293	Ultrasonic/electronic aerosol generator with small volume nebulizer	03/11/21	
	0271, 0291, 0292,			
E0575	0293	Nebulizer, ultrasonic, large volume	03/11/21	
	0271, 0291, 0292,	Nebulizer, durable, glass or autoclavable plastic, bottle type, for use with		
E0580	0293	regulator or flowmeter	03/11/21	
	0271, 0291, 0292,			
E0585	0293	Nebulizer, with compressor and heater	03/11/21	
	0271, 0291, 0292,			
E0600	0293	Respiratory suction pump, home model, portable or stationary, electric	03/11/21	
	0271, 0291, 0292,			
E0605	0293	Vaporizer, room type	03/11/21	
E1352	0271, 0294	Oxygen accessory, flow regulator capable of positive inspiratory pressure	03/11/21	
	0271, 0294, 0600,			
71050	0601, 0602, 0603,		00/11/01	
E1353	0604, 0609	Regulator	03/11/21	
	0271, 0294, 0600,			
F1050	0601, 0602, 0603,		00/11/01	
E1372	0604, 0609	Immersion external heater for nebulizer	03/11/21	
	0271, 0294, 0600,			
E1200	0601, 0602, 0603,	Oxygen concentrator, single delivery port, capable of delivering 85 percent	02/11/01	
E1390	0604, 0609	or greater oxygen concentration at the prescribed flow rate	03/11/21	
	0271, 0294, 0600,			
E1201	0601, 0602, 0603,	Oxygen concentrator, dual delivery port, capable of delivering 85 percent or	02/11/01	
E1391	0604, 0609	greater oxygen concentration at the prescribed flow rate, each	03/11/21	
	0271, 0294, 0600,			
E1202	0601, 0602, 0603,	Doutship any son contrator routsi	02/11/01	
E1392	0604, 0609	Portable oxygen concentrator, rental	03/11/21	
E2208	0271, 0294	Wheelchair accessory, cylinder tank carrier, each	03/11/21	
K0730	0271, 0294	Controlled dose inhalation drug delivery system	03/11/21	

	0271, 0291, 0292,			
	0293, 0600, 0601,	Portable gaseous oxygen system, rental; home compressor used to fill		
	0602, 0603, 0604,	portable oxygen cylinders; includes portable containers, regulator,		
K0738	0609, 0946	flowmeter, humidifier, cannula or mask, and tubing	03/11/21	
G0008	0771	Administration of influenza virus vaccine	03/11/21	
G0009	0771	Administration of pneumococcal vaccine	03/11/21	
		Federally qualified health center (FQHC) visit, new patient; a medically-		
		necessary, face-to-face encounter (one-on-one) between a new patient and a		
		FQHC practitioner during which time one or more FQHC services are		
	0521, 0522, 0524,	rendered and includes a typical bundle of Medicare-covered services that		
G0466	0525, 0527, 0528	would be furnished per diem to a patient receiving a FQHC visit	03/11/21	
		Federally qualified health center (FQHC) visit, established patient; a		
		medically-necessary, face-to-face encounter (one-on-one) between an		
		established patient and a FQHC practitioner during which time one or more		
	0.501 0.500 0.501	FQHC services are rendered and includes a typical bundle of Medicare-		
G0.467	0521, 0522, 0524,	covered services that would be furnished per diem to a patient receiving a	02/11/01	
G0467	0525, 0527, 0528	FQHC visit	03/11/21	
		Prolonged office or other outpatient evaluation and management service(s)		
		beyond the maximum required time of the primary procedure which has		
		been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional,		
		with or without direct patient contact (list separately in addition to CPT		
		codes 99205, 99215 for office or other outpatient evaluation and		
	0510, 0513, 0516,	management services) (do not report g2212 on the same date of service as		
	0517, 0519, 0520,	99354, 99355, 99358, 99359, 99415, 99416). (do not report g2212 for any		
G2212	0526, 0529	time unit less than 15 minutes)	03/11/21	
J0278	0250, 0636	Injection, amikacin sulfate, 100 mg	03/11/21	
J0290	0250, 0636	Injection, ampicillin sodium, 500 mg	03/11/21	
J0295	0250, 0636	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	03/11/21	
J0740	0250, 0636	Injection, cidofovir, 375 mg	03/11/21	
J1180	0250, 0636	Injection, dyphylline, up to 500 mg	03/11/21	
J1335	0250, 0636	Injection, ertapenem sodium, 500 mg	03/11/21	
J1364	0636	Injection, erythromycin lactobionate, per 500 mg	03/11/21	
		Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g.,		
J1459	0636	liquid), 500 mg	03/11/21	
J1460	0636	Injection, gamma globulin, intramuscular, 1 cc	03/11/21	
J1556	0636	Injection, immune globulin (bivigam), 500 mg	03/11/21	
J1559	0636	Injection, immune globulin (Hizentra), 100 mg	03/11/21	

J1560	0636	Injection, gamma globulin, intramuscular, over 10 cc	03/11/21	
		Injection, immune globulin, (Gamunex-C/Gammaked), non-lyophilized		
J1561	0636	(e.g., liquid), 500 mg	03/11/21	
J1562	0636	Injection, immune globulin (Vivaglobin), 100 mg	03/11/21	
		Injection, immune globulin, intravenous, lyophilized (e.g., powder), not		
J1566	0636	otherwise specified, 500 mg	03/11/21	
		Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g.,		
J1568	0636	liquid), 500 mg	03/11/21	
		Injection, immune globulin, (Gammagard liquid), non-lyophilized, (e.g.,		
J1569	0636	liquid), 500 mg	03/11/21	
		Injection, immune globulin, (Flebogamma/Flebogamma Dif), intravenous,		
J1572	0636	non-lyophilized (e.g., liquid), 500 mg	03/11/21	
		Injection, immune globulin/hyaluronidase, (HYQVIA), 100 mg		
J1575	0636	immuneglobulin	03/11/21	
J1580	0250, 0636	Injection, garamycin, gentamicin, up to 80 mg	03/11/21	
J1840	0250, 0636	Injection, kanamycin sulfate, up to 500 mg	03/11/21	
J1850	0636	Injection, kanamycin sulfate, up to 75 mg	03/11/21	
J2010	0250, 0636	Injection, lincomycin HCl, up to 300 mg	03/11/21	
J2250	0250, 0636	Injection, midazolam hydrochloride, per 1 mg	03/11/21	
J2510	0250, 0636	Injection, penicillin G procaine, aqueous, up to 600, 000 units	03/11/21	
J2540	0250, 0636	Injection, penicillin G potassium, up to 600, 000 units	03/11/21	
		Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams		
J2543	0250, 0636	(1.125 grams)	03/11/21	
		Pentamidine isethionate, inhalation solution, FDA-approved final product,		
J2545	0636	non-compounded, administered through DME, unit dose form, per 300 mg	03/11/21	
J2700	0250, 0636	Injection, oxacillin sodium, up to 250 mg	03/11/21	
J2810	0250, 0636	Injection, theophylline, per 40 mg	03/11/21	
J3000	0250, 0636	Injection, streptomycin, up to 1 gm	03/11/21	
J3105	0250, 0636	Injection, terbutaline sulfate, up to 1 mg	03/11/21	
J3260	0250, 0636	Injection, tobramycin sulfate, up to 80 mg	03/11/21	
J3285	0636	Injection, treprostinil, 1 mg	03/11/21	
J3320	0636	Injection, spectinomycin dihydrochloride, up to 2 gm	03/11/21	
J7510	0250, 0636	Prednisolone oral, per 5 mg	03/11/21	
J7512	0250, 0636	Prednisone, immediate release or delayed release, oral, 1 mg	03/11/21	
		Acetylcysteine, inhalation solution, compounded product, administered		
J7604	0294	through DME, unit dose form, per gram	03/11/21	
		Acetylcysteine, inhalation solution, FDA-approved final product, non-		
J7608	0294	compounded, administered through DME, unit dose form, per gram	03/11/21	

		Albuterol, inhalation solution, compounded product, administered through	
J7609	0294	DME, unit dose, 1 mg	03/11/21
		Albuterol, inhalation solution, compounded product, administered through	00/11/01
J7610	0294	DME, concentrated form, 1 mg	03/11/21
		Albuterol, inhalation solution, FDA-approved final product, non-	00/44/04
J7611	0294	compounded, administered through DME, concentrated form, 1 mg	03/11/21
		Levalbuterol, inhalation solution, FDA-approved final product, non-	
J7612	0294	compounded, administered through DME, concentrated form, 0.5 mg	03/11/21
		Albuterol, inhalation solution, FDA-approved final product, non-	
J7613	0294	compounded, administered through DME, unit dose, 1 mg	03/11/21
		Levalbuterol, inhalation solution, FDA-approved final product, non-	
J7614	0294	compounded, administered through DME, unit dose, 0.5 mg	03/11/21
		Levalbuterol, inhalation solution, compounded product, administered	
J7615	0294	through DME, unit dose, 0.5 mg	03/11/21
		Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-	
J7620	0294	approved final product, non-compounded, administered through DME	03/11/21
		Budesonide, inhalation solution, FDA-approved final product, non-	
J7626	0294	compounded, administered through DME, unit dose form, up to 0.5 mg	03/11/21
		Budesonide, inhalation solution, compounded product, administered through	
J7627	0294	DME, unit dose form, up to 0.5 mg	03/11/21
		Cromolyn sodium, inhalation solution, FDA-approved final product, non-	
J7631	0294	compounded, administered through DME, unit dose form, per 10 milligrams	03/11/21
		Cromolyn sodium, inhalation solution, compounded product, administered	
J7632	0294	through DME, unit dose form, per 10 milligrams	03/11/21
		Dornase alfa, inhalation solution, FDA-approved final product, non-	
J7639	0294	compounded, administered through DME, unit dose form, per milligram	03/11/21
		Formoterol, inhalation solution, compounded product, administered through	
J7640	0636	DME, unit dose form, 12 micrograms	03/11/21
		Glycopyrrolate, inhalation solution, compounded product, administered	
J7642	0294	through DME, concentrated form, per milligram	03/11/21
		Glycopyrrolate, inhalation solution, compounded product, administered	
J7643	0294	through DME, unit dose form, per milligram	03/11/21
		Ipratropium bromide, inhalation solution, FDA-approved final product, non-	
J7644	0294	compounded, administered through DME, unit dose form, per milligram	03/11/21
		Ipratropium bromide, inhalation solution, compounded product,	
J7645	0294	administered through DME, unit dose form, per milligram	03/11/21
		Isoetharine HCl, inhalation solution, compounded product, administered	
J7650	0294	through DME, unit dose form, per milligram	03/11/21

MaineCare COVID-19 Billing Codes

		Metaproterenol sulfate, inhalation solution, compounded product,	
J7667	0294	concentrated form, per 10 milligrams	03/11/21
		Metaproterenol sulfate, inhalation solution, FDA-approved final product,	
		non-compounded, administered through DME, concentrated form, per 10	
J7668	0294	milligrams	03/11/21
		Metaproterenol sulfate, inhalation solution, FDA-approved final product,	
		non-compounded, administered through DME, unit dose form, per 10	
J7669	0294	milligrams	03/11/21
		Metaproterenol sulfate, inhalation solution, compounded product,	
J7670	0294	administered through DME, unit dose form, per 10 milligrams	03/11/21
		Tobramycin, inhalation solution, FDA-approved final product, non-	
		compounded, unit dose form, administered through DME, per 300	
J7682	0294	milligrams	03/11/21
		Tobramycin, inhalation solution, compounded product, administered through	
J7685	0294	DME, unit dose form, per 300 milligrams	03/11/21
Q5108	0636	Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg	03/11/21
Q5110	0636	Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram	03/11/21
S8096	0290, 0292, 0299	Portable peak flow meter	03/11/21